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Abstract
Amino-terminal acetylation is a co-translational process that occurs on a majority of all eukaryotic proteins.
This modification mediates a wide range of biological processes including but not limited to cellular apoptosis,
enzyme regulation, protein localization and the N-end rule for protein degradation. The amino-terminal
acetyltransferase (NAT) enzymes that catalyze this reaction are distinguished from one another on the basis
of substrate specificity, which is dictated by the identity of the amino-terminal sequence of the substrate
protein. The NatA complex harbors the greatest diversity for substrate selection and is responsible for
acetylating a majority of all proteins that undergo this modification in vivo. Interestingly, the major NATs exist
as obligate heterodimers with one unique catalytic subunit and an additional unique auxiliary subunit that
both activates the catalytic component and anchors the complex to the ribosome. Aberrant expression of the
NatA catalytic subunit, Naa10p, as well as the auxiliary subunit, Naa15p, has been found in numerous cancer
cell tissues; consequently, NatA is an emerging target for chemotherapeutic development.
Despite the ubiquitous nature of this modification as well as its role in oncogenesis, there is no structural data
available for any eukaryotic NAT protein. Inspired by this, we determined the x-ray crystal structures of a
series of NAT enzymes, highlighted by the structure of the 100 kDa NatA complex in the absence and
presence of a bisubstrate peptide-CoA conjugate inhibitor as well as the structure of the uncomplexed Naa10p
catalytic subunit. Additionally, we determined the structure of the independently active NatE bound to CoA
and a substrate peptide fragment and the structure of an archaeal NAT enzyme that acetylates NatA and NatE
substrates. These structures and accompanying biochemical assays are used to delineate mechanisms of
substrate binding specificity and catalysis employed by this family of enzymes. This work provides the first
scaffold for the design of NAT-specific inhibitors and lays a foundation for understanding NAT activity at the
molecular level. Furthermore, this study could have implications for mechanisms by which regulatory
subunits modulate the activity of the broader family of protein acetyltransferases.
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ABSTRACT 
 
THE MOLECULAR BASIS FOR AMINO-TERMINAL ACETYLATION BY NAT 
PROTEINS 
 
 
Glen Liszczak 
Ronen Marmorstein 
 
Amino-terminal acetylation is a co-translational process that occurs on a majority 
of all eukaryotic proteins.  This modification mediates a wide range of biological 
processes including but not limited to cellular apoptosis, enzyme regulation, protein 
localization and the N-end rule for protein degradation.  The amino-terminal 
acetyltransferase (NAT) enzymes that catalyze this reaction are distinguished from one 
another on the basis of substrate specificity, which is dictated by the identity of the 
amino-terminal sequence of the substrate protein.  The NatA complex harbors the 
greatest diversity for substrate selection and is responsible for acetylating a majority of 
all proteins that undergo this modification in vivo.  Interestingly, the major NATs exist as 
obligate heterodimers with one unique catalytic subunit and an additional unique 
auxiliary subunit that both activates the catalytic component and anchors the complex to 
the ribosome.  Aberrant expression of the NatA catalytic subunit, Naa10p, as well as the 
   vii 
auxiliary subunit, Naa15p, has been found in numerous cancer cell tissues; consequently, 
NatA is an emerging target for chemotherapeutic development. 
Despite the ubiquitous nature of this modification as well as its role in 
oncogenesis, there is no structural data available for any eukaryotic NAT protein.  
Inspired by this, we determined the x-ray crystal structures of a series of NAT enzymes, 
highlighted by the structure of the 100 kDa NatA complex in the absence and presence of 
a bisubstrate peptide-CoA conjugate inhibitor as well as the structure of the uncomplexed 
Naa10p catalytic subunit.  Additionally, we determined the structure of the independently 
active NatE bound to CoA and a substrate peptide fragment and the structure of an 
archaeal NAT enzyme that acetylates NatA and NatE substrates.  These structures and 
accompanying biochemical assays are used to delineate mechanisms of substrate binding 
specificity and catalysis employed by this family of enzymes.    This work provides the 
first scaffold for the design of NAT-specific inhibitors and lays a foundation for 
understanding NAT activity at the molecular level.  Furthermore, this study could have 
implications for mechanisms by which regulatory subunits modulate the activity of the 
broader family of protein acetyltransferases. 
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CHAPTER 1 
 
Amino-terminal acetylation:  It’s not your average birthmark 
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1.1  Protein acetylation 
Currently, there are thought to be 20,000-25,000 protein-coding genes in the 
human genome (Clamp et al., 2007).  Roughly 5% of these genes are dedicated to 
enzymes that catalyze a variety of covalent protein modifications, which are able to 
greatly diversify the proteome by altering the function and dynamics of expressed 
proteins (Walsh et al., 2005).  One of the most abundant covalent protein modifications is 
acetylation, which occurs predominantly at the ε-amino group of side chain lysines and 
the α-amino group at the amino-terminus of a protein (Arnesen et al., 2009; Choudhary et 
al., 2009).  Protein acetylation is catalyzed by bisubstrate acetyltransferase enzymes, 
which facilitate the transfer of the acetyl group from the cofactor acetyl coenzyme A 
(AcCoA) to a substrate protein (Figure 1.1) (Hodawadekar and Marmorstein, 2007; 
Soppa, 2010).  The acetylation modification neutralizes the positively charged amino 
group and can effect protein-protein complex formation, protein folding, protein 
degradation, and enzymatic activity, among many other processes (Kouzarides, 2000; 
Starheim et al., 2012; Yuan and Marmorstein, 2013).   
Histone side chain lysine acetylation is the most well characterized form of 
protein acetylation (Grunstein, 1997; Sterner and Berger, 2000).  Acetylation of histones 
was discovered in 1964 and the connection between histone acetylation status and 
transcription was immediately established (Allfrey et al., 1964).  Since then, a number of 
histone acetyltransferases have been biochemically and structurally characterized, and in 
vivo studies have explored the role of histone acetylation in transcriptional activation and 
repression through regulation of DNA-histone interactions as well as in recruitment 
bromodomain-containing transcription-associated proteins (Carrozza et al., 2003; Kuo 
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and Allis, 1998; Marmorstein, 2004; Wang et al., 2008; Yun et al., 2011).  Recently, the 
significance and extensiveness of non-histone lysine side chain acetylation was explored 
in a mass spectrometry analysis of the proteome in which a great number of acetylation 
sites were identified on ~1750 non-histone proteins (Choudhary et al., 2009).   
Comparatively speaking, despite the fact that amino-terminal acetylation was discovered 
in 1958 and shown to occur on ~80% of all proteins by 1976, it is not well characterized 
(Brown and Roberts, 1976; Narita, 1958).  However, in the past decade there have been a 
number of studies implicating the overexpression of amino-terminal acetyltransferases 
(NATs) in oncogenesis, and as a result there has been an explosion of research activity in 
the field of amino-terminal acetylation (Arnesen, 2011; Kalvik and Arnesen, 2013; 
Starheim et al., 2012).  
During translation, the nascent peptide chain can undergo a variety of 
modifications as it emerges from the ribosome, with the two most common being 
methionine excision and amino-terminal acetylation (Bradshaw et al., 1998; Kramer et 
al., 2009).  In eukaryotes, the co-translational process of N-terminal methionine excision 
occurs on ~70% of all proteins when ~15 residues of the growing peptide are protruding 
from the ribosome (Giglione et al., 2004).  This process is catalyzed by the methionine 
aminopeptidases (MAPs) when the second residue of the substrate protein contains a 
nonbulky side chain resulting in an amino-terminal Ala-, Cys-, Gly-, Pro-, Ser-, Thr-, or 
Val-.  Amino-terminal acetylation occurs when there are between 25 and 50 residues 
extruding from the ribosome, and is catalyzed by NAT enzymes in a sequence-specific 
manner (Driessen et al., 1985; Gautschi et al., 2003; Polevoda and Sherman, 2003b).  
Numerous studies have shown that amino-terminal acetylation is a very ubiquitous 
   4 
modification, occurring on ~80% of all human proteins, ~50% of all yeast proteins and 
~20% of archaeal proteins (Aivaliotis et al., 2007; Arnesen et al., 2009; Helbig et al., 
2010; Kirkland et al., 2008).  In bacteria, there are only a handful of proteins that undergo 
this modification (Waller, 1963).  Presently, amino-terminal acetylation is believed to be 
an irreversible process and that only occurs post-translationally in a select few cases (Van 
Damme et al., 2011a).  There are several labs that are actively trying to identify amino-
terminal deacetylases as well as expand the post-translational amino-terminal acetylation 
profile.  
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Figure 1.1  Protein acetylation by acetyltransferase enzymes.  Histone 
acetyltransferases (HATs) and other internal lysine acetyltransferases (KATs) use 
AcCoA to catalyze the acetylation of ε-amino groups on internal lysine side chains.  
Amino-terminal acetyltransferases use AcCoA to catalyze the acetylation of α-amino 
groups on amino terminal residues.  The products generated from the acetylation reaction 
are acetylated peptide and CoA.     
   6 
1.2  Biological significance of amino-terminal acetylation 
Inspired by the link of aberrant expression of NATs to carcinogenesis, the 
functional consequences of amino-terminal acetylation are beginning to be explored in 
greater detail.  While the reason that a majority of proteins undergo this modification is 
still not fully understood, several key findings published recently unveil molecular 
mechanisms by which amino-terminal acetylation is able to regulate a variety of 
biological processes. 
The N-end rule for protein degradation was discovered in 1986 and relates the in 
vivo half-life a protein to the identity of its N-terminal residue (Bachmair et al., 1986).  
Briefly, there exist E3 ubiquitin ligases that are able to recognize certain ‘destabilizing 
residues’ at the amino terminus of a protein, which leads to ubiquitination and eventually 
degradation (Figure 1.2A) (Varshavsky, 2011).  Several of the residues that are not 
directly recognized by these E3 ligases can be modified in a one or two step process that 
eventually results in an amino-terminal arginine, which is a destabilizing residue.  
Interestingly, no residue that can undergo amino-terminal acetylation can be marked for 
degradation by the mechanisms described in the traditional N-end rue pathway.  The N-
end rule underwent a significant expansion in 2010 when Varshavsky and colleagues 
reported that an amino-terminal acetyl mark could be recognized by the ubiquitin ligase 
Doa10 which would subsequently lead to degradation (Figure 1.2B) (Hwang et al., 2010).  
This study showed that proteins could not be degraded via this pathway in the absence of 
the Doa10 E3 ligase or the NAT enzymes that catalyze acetylation of the target proteins.  
This augmentation of the N-end rule is conserved from yeast to humans and is the first 
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universally applicable functional consequence of amino-terminal acetylation to be 
described.   
Bromodomains are protein motifs that recognize acetylated lysine residues and 
mediate protein-protein interactions (Filippakopoulos et al., 2012; Mujtaba et al., 2007).  
It has long been thought that a bromodomain-like motif exists for recognition of amino-
terminal acetylation.  In 2011, a domain within the E3 ligase Dcn1 that specifically 
recognizes an amino-terminal acetyl group to facilitate protein complex formation was 
reported (Scott et al., 2011).  The x-ray crystal structure of this protein in complex with 
an amino-terminal peptide fragment corresponding to its E2 ligase binding partner 
(Ubc12) highlights a hydrophobic pocket capable of distinguishing between an amino-
terminal acetyl group and other similar marks such as an amino-terminal formyl group or 
an internal lysine acetyl group (Figure 1.3A).  Furthermore, substrate neddylation by 
Dcn1 is dependent upon amino-terminal acetylation of the Ubc12 protein.  This study is 
the first to present a cellular process that is regulated by amino-terminal acetylation 
through control of protein-protein interactions, and it is tempting to speculate that there 
exist many other proteins with a similar recognition motif that have not yet been 
characterized. 
The amino terminus of a protein frequently contains a signal sequence that allows 
it to be targeted to the endoplasmic reticulum (ER) for post-translational processing and 
secretion (Rapoport, 1992).  In a study of the effect of amino-terminal acetylation on 
signal sequences, it was found that cytosolic proteins were heavily biased in favor of 
amino-terminal acetylation while an equal and opposite bias was observed for secretory 
proteins, which must undergo ER translocation (Forte et al., 2011).  This study also 
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shows that when an acetyl group is introduced to a protein that commonly undergoes 
translocation, that protein is retained in the cytosol, suggesting this modification plays a 
significant role in controlling protein localization (Figure 1.3B).  The authors propose 
that the signal recognition particle, which recognizes and targets specific proteins to the 
translocon, is able to protect acetylatable amino-termini during translation to ensure 
proper protein trafficking. 
Metabolic regulation of NAT activity has also been observed in a study that links 
amino-terminal acetylation to apoptosis (Yi et al., 2011).  Overexpression of the anti-
apoptotic factor Bcl-xL has been shown to lower AcCoA levels by blocking secretion of 
critical AcCoA precursors from the mitochondria.  As a result of this decreased AcCoA 
level in the cell, there is a population of proteins that do not undergo amino-terminal 
acetylation.  This study focuses on the effect that Bcl-xL overexpression has on a group 
of caspases that must be amino-terminally acetylated to induce apoptosis (Figure 1.3C). 
The experimental results from this paper suggest that when Bcl-xL is upregulated in cells, 
these caspases are not amino-terminally acetylated in cells and apoptosis cannot be 
carried out through this pathway.  
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Figure 1.2  The N-end rule for protein degradation.  (A) The arginine pathway 
includes primary destabilizing residues (black single letter amino acid representation) that 
are directly recognized by E3 ligases, ubiquitinated and subsequently degraded by the 
proteasome.  Secondary residues (blue amino acid letters) are not directly recognized by 
any E3 ligases but can be amino-terminally arginylated (green lettering) by arginine 
transferases (Ate1) to inherit a primary destabilizing amino-terminal residue.  Tertiary 
residues (green amino acid letters) must be deamidated by Nta1 to become secondary 
residues, which again are arginylated to become primary residues.  (B) In the amino-
terminal acetylation pathway, all residues are initially secondary destabilizing residues, 
which are converted to primary residues via NAT proteins.  E3 ligases can recognize the 
amino-terminal acetylation mark (green lettering) and ubiquitinate the protein, marking it 
for degradation by the proteasome.  This figure has been adapted from Varshavsky, 2011. 
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Figure 1.3  Amino-terminal acetylation can mediate protein-protein interactions, 
protein localization and apoptosis.  (caption on following page) 
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Figure 1.3 (continued) (A) Amino-terminal acetylation facilitates the interaction 
between the E3 ligase Ubc12 (teal) and the E2 ligase Dcn1 (shown with conservation 
surface).  This amino-terminal acetylation-recognition pocket is conserved from yeast to 
humans. (B) Amino-terminal acetylation of an endoplasmic ER signaling sequence has 
been shown to inhibit protein translocation into the ER.  (C) Bcl-xL (orange) blocks 
secretion of citrate from the mitochondria, which reduces overall AcCoA production by 
the cell.  As a result, certain apoptotic effectors can no longer undergo amino-terminal 
acetylation and defects in apoptosis are observed.  This figure has been adapted from 
Scott et al., 2011 and Starheim et al., 2012. 
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1.3  Amino-terminal acetyltransferases in cancer 
As evidenced by the role of amino-terminal acetylation in a wide variety of 
cellular pathways, particularly apoptosis and protein degradation, it would seem that a 
delicate balance of amino terminal acetylation is required for proper cellular function.  
Indeed, aberrant expression of NAT enzymes has been observed in numerous cancer cell 
tissues.  Interestingly, NATH (Naa15p), a component of the NatA complex, was 
originally identified as an overexpressed gene in thyroid carcinoma tissues relative to 
non-cancerous thyroid tissue (Fluge et al., 2002).  This gene was soon found to also be 
overexpressed in gastric cancer as well while its binding partner hARD1 (Naa10p) was 
found to be significantly overexpressed in hepatocellular carcinomas as well as colorectal 
cancer tissue, breast cancer tissue and lung cancer tissue (Kalvik and Arnesen, 2013; Lim 
et al., 2006; Line et al., 2002; Midorikawa et al., 2002; Ren et al., 2008; Yu et al., 2009a; 
Yu et al., 2009b). 
The mechanisms by which overexpression of NAT proteins stimulate cellular 
proliferation and assist in evasion of apoptosis are still being worked out, but several 
studies have implicated NATs in cell cycle progression and the DNA damage response 
(Arnesen et al., 2006b; Gromyko et al., 2010; Lim et al., 2006).  In breast cancer, Naa10p 
was found to promote passage of the G1/S and G2/M checkpoints in the cell cycle, 
resulting in hyperproliferation of the MCF-7 breast cancer cell line under investigation 
(Yu et al., 2009b).  In a separate study, depletion of Naa10p was correlated with the 
activation and stabilization of the p53 tumor suppressor protein (Gromyko et al., 2010).  
As a result of Naa10p knockdown, an increase in transcription of pro-apoptotic p53-
dependent genes is observed in response to DNA damage and normal apoptotic pathways 
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can be carried out.  Additional studies are required to analyze whether the half-life of p53 
is increased as a result of decreased NAT activity or if the stabilization is through an 
alternate mechanism.   
As a consequence of the observations described above, NAT enzymes are 
emerging targets for chemotherapeutic development (Arnesen et al., 2008).  One study 
used siRNA to knock down Naa10p expression in thyroid cancers with misregulation of 
p53 and observed an increase in apoptotic cells (Gromyko et al., 2010).  Another study 
used siRNA to analyze the effect of Naa10p and Naa15p knockdown in HeLa cells and 
observed a significant increase in the percent of apoptotic cells when NAT activity is 
decreased (Figure 1.4A) (Arnesen et al., 2006b).  Furthermore, the activity of the 
apoptosis-inducing drug daunorubicin was increased ~5-fold in the presence of siRNA 
targeting the Naa10p NAT (Figure 1.4B) (Gromyko et al., 2010).  These results are able 
to show that inhibiting NAT activity can induce apoptosis in a variety of cancer cell 
tissues and that the development of potent and selective cell-permeable inhibitors is a 
worthwhile endeavor.  A lack of biochemical and structural characterization of these 
enzymes has left mechanisms of substrate binding and catalysis nebulous and as a result, 
inhibitor development will be very challenging.  Moreover, NATs are likely to share a 
high degree of structural homology with HATs, which are another popular drug target.  
Structural characterization of NAT enzymes will allow help to elucidate key differences  
between these two families of enzymes and aid in the development of inhibitors that 
specifically target NATs over HATs and vice versa (Arnesen et al., 2005).   
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Figure 1.4  Knockdown of the NatA complex can induce cell death in multiple 
cancer cell lines. (A) HeLa cells (cervical cancer cell line) were transfected with 100 nM 
hARD1 siRNA (siA1-2), NATH siRNA (siN-1), combination of NATH and hARD1 
siRNAs (100 nM each), control siRNA (siL-100 and siL-200) or transfected with 
Oligofectamine only (siRNA-).  The percent of apoptotic cells resulting from each siRNA 
transfection is shown. (B) Depletion of NatA sensitized CAL-62 cells (thyroid cancer cell 
line) to treatment with the Daunorubicin, a DNA intercalating drug that is FDA approved 
for the treatment of certain cancers. Reductions in cellular proliferation are shown.  This 
figure has been adapted from Arnesen et al., 2006b and Gromyko et al., 2010. 
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1.4  Amino-terminal acetyltransferase enzymes 
There are three major NAT complexes that are responsible for modifying ~85% 
of all proteins that undergo amino-terminal acetylation in vivo (Arnesen et al., 2009; 
Starheim et al., 2009b).  These complexes, called NatA, NatB and NatC, are well 
conserved from yeast to humans, exist as obligate heterodimers, and are differentiated 
from one another on the basis of substrate specificity (Figure 1.5A) (Polevoda et al., 
1999; Polevoda and Sherman, 2003a).  Each complex consists of one unique catalytic 
subunit and an additional unique auxiliary subunit that both activates the enzymatic 
component and anchors the complex to the ribosome during translation (Gautschi et al., 
2003; Polevoda et al., 2008).  Three additional NAT enzymes, NatD-NatF, have also 
been identified but they have a limited set of biologically relevant substrates, appear to be 
independently active, and are not well characterized across eukaryotes (Evjenth et al., 
2009; Gautschi et al., 2003; Hole et al., 2011; Polevoda et al., 2009; Song et al., 2003; 
Van Damme et al., 2011b). 
The NatA complex harbors the most diversity for substrate selection and is 
responsible for modifying the majority of all amino-terminally acetylated proteins in vivo 
(Arnesen et al., 2009; Polevoda et al., 1999).  NatA is the only NAT complex with the 
ability to acetylate the α-amino group of non-methionine amino-terminal residues; it will 
acetylate an α-amino group of an amino-terminal Ala-, Cys-, Gly-, Ser-, Thr-, or Val- on 
a nascent peptide chain (Polevoda and Sherman, 2003b).  Interestingly, the only NAT 
proteins that have been found to be upregulated in cancer are components of the NatA 
complex, making this NAT the most clinically relevant of all the NAT enzymes (Kalvik 
and Arnesen, 2013).  
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The heterodimeric NatA complex contains the Naa10p catalytic subunit (MW~20 
kDa) and the Naa15p auxiliary subunit (MW~80 kDa) (Arnesen et al., 2005; Mullen et 
al., 1989; Park and Szostak, 1992).  Naa10p is believed to be a member of the GNAT 
family of acetyltransferases based on the similarity of its sequence to known GNAT 
proteins (Vetting et al., 2005).  There is comparatively far less known about the structure 
and activating mechanism of Naa15p, largely owing to the fact that there are no proteins 
with appreciable sequence similarity that have been structurally characterized.  Protein 
domain identification servers have been used to analyze the sequence of Naa15p and 
predict that it contains a coiled coil region and at least 4 tetratricopeptide (TPR) motifs 
(Arnesen et al., 2005; Blatch and Lassle, 1999).  Notably, biochemical characterization of 
NatA has been hampered by the fact that there is currently no protocol available for 
recombinant expression of the complex. 
The NatB and NatC complexes are also obligate heterodimers that can physically 
associate with the ribosome (Polevoda et al., 2003; Rigaut et al., 1999; Starheim et al., 
2008; Starheim et al., 2009a; Tercero and Wickner, 1992; Van Damme et al., 2012).  A 
third subunit of the NatC complex has been identified that may enhance activity of the 
dimer, but is not required for activity (Polevoda and Sherman, 2001).  Both of these 
complexes acetylate the α-amino group of substrate peptides with an amino-terminal 
methionine residue, with further specificity dependent up the identity of the second 
residue; NatB is active towards peptides with a hydrophilic second residue while NatC is 
active towards peptides with a hydrophobic second residue (Polevoda et al., 1999; 
Polevoda and Sherman, 2003b; Tercero et al., 1993).  Like NatA, there is no structural 
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data available for any component of either of these complexes and recombinant 
expression of the complexes has not yet been worked out.   
Of the three NATs that show activity in the absence of a regulatory protein 
subunit (NatD-NatF), NatE (Naa50p) is the only one that has been recombinantly 
expressed (Evjenth et al., 2009).  In a recent study focused on the biochemical 
characterization of Naa50p, the recombinant protein was able to acetylate the α-amino 
group of a peptide with an amino-terminal Met-Leu-Gly-Pro- sequence, which 
corresponds to the protein hnRNP F, the only Naa50p substrate identified in vivo 
(Arnesen et al., 2009).  Additional kinetic analysis revealed that while the amino-terminal 
methionine is required for activity, the identity of downstream residues is less crucial 
(Figure 1.5B) (Evjenth et al., 2009).  Despite the fact that only one biologically relevant 
substrate is known, the Naa50p enzyme was shown to be required for proper sister 
chromatid cohesion in humans and fruit flies, a process that does not involve the hnRNP 
F protein (Hou et al., 2007; Pimenta-Marques et al., 2008; Williams et al., 2003).  It is 
therefore likely that this enzyme has other biologically relevant substrates that have not 
yet been identified.  The enzyme was also screened against many proteins known to 
contain acetylation-susceptible internal lysines and no significant acetylation could be 
detected (Evjenth et al., 2009).  Interestingly, this protein has been found to physically 
associate with the NatA complex (Arnesen et al., 2006a; Gautschi et al., 2003).  
Preliminary experiments show that Naa50p is not catalytically stimulated by this 
interaction, suggesting that recruitment to the ribosome is likely to be the sole purpose for 
this interaction (data not shown).   
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Figure 1.5  NAT substrate specificities.  (A) The three known eukaryotic NAT 
complexes are shown bound to a translating ribosome.  The substrate specificities for 
each NAT are listed below the complex corresponding complex. (B) Biochemical 
characterization of NatE with a variety of substrate peptides.  The ‘RRR24’ portion of the 
peptide represents a 20-amino acid basic tag that was used to isolate the peptide after the 
acetylation reaction.  This figure has been adapted from Starheim et al., 2012 and Evjenth 
et al., 2009. 
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1.5  Dissertation objectives 
There is a substantial lack of biochemical and structural data available for 
enzymes that facilitate the very ubiquitous modification of amino-terminal acetylation.  
Currently, the bacterial RimI enzyme is the only NAT structure available and 
mechanisms of substrate binding and catalysis employed by NAT enzymes remain 
mostly unexplored (Vetting et al., 2008).  Structural and biochemical characterization of 
NATs, particularly the NatA complex, would uncover unique features that could be 
exploited for the development of potent and specific inhibitors with chemotherapeutic 
application (Arnesen et al., 2008).  Furthermore, in the broader family of 
acetyltransferases, there are several enzymes that require binding partners for catalytic 
activity such as HAT1, Sas2 and HBO1 (Iizuka and Stillman, 1999; Parthun et al., 1996; 
Sutton et al., 2003).  Despite the observation that many acetyltransferases require 
regulatory subunits for optimal activity, no acetyltransferase has been characterized in the 
presence of its activating partner.   
The focus of my dissertation is on determining the molecular basis for substrate 
binding, acetylation specificity, and catalysis exhibited by the NatA complex, and to 
determine the role of the auxiliary subunit in these activities.  I also set out to structurally 
and biochemically characterize the Naa50p enzyme, which independently acetylates 
substrates with a Met- amino-terminal residue.  To this end I solved the structure of 
Naa50p bound to a substrate peptide as well as the structure of Naa10p in the absence and 
presence of the Naa15p regulatory subunit and a bisubstrate inhibitor.  Additionally, I 
characterized an archaeal NAT that is able to acetylate NatA and Naa50p substrates.  
This study was able to validate the mechanisms I proposed for acetylation by NatA and 
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Naa50p and also has implications for the evolution of substrate-specific acetylation by 
eukaryotic NAT enzymes.  Through the use of x-ray crystallography and structure-based 
biochemical assays I was able to: 
(1)  Identify mechanisms by which these enzymes are able to preferentially acetylate 
α-amino groups over ε-amino groups. 
(2) Show a conserved NAT tertiary structure that appears to be required for catalytic 
activity. 
(3) Uncover the mechanisms that these enzymes use to acetylate substrates in a 
sequence-specific manner. 
(4) Characterize the first mechanism of acetyltransferase activation by an obligate 
binding partner. 
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CHAPTER 2 
 
Structure of the ternary Naa50p amino-terminal acetyltransferase complex reveals 
the molecular basis for substrate-specific acetylation 
 
 
 
 
 
 
 
 
 
 
 
"This research was originally published in the Journal of Biological Chemistry (Liszczak 
et al., 2011) © the American Society for Biochemistry and Molecular Biology."
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2.1  Introduction and summary of conclusions 
To understand the molecular basis for how NAT proteins such as Naa50p mediate 
catalysis and selectively target the α-amino group of amino-terminal residues over the ε-
amino group of side-chain lysine residues, we determined the x-ray crystal structure of a 
ternary Naa50p complex with coenzyme A and a cognate amino-terminal substrate 
peptide, and carried out structure based mutagenesis as well as accompanying 
biochemical and enzymatic characterization. We find that the peptide backbone of the 
substrate is anchored to the protein through a series of backbone hydrogen bonds with the 
first methionine residue specified through multiple van der Waals contacts, together 
creating an α-amino methionine-specific pocket.  We also employ structure-based 
mutagenesis that supports the importance of the α-amino methionine-specific pocket of 
Naa50p and is consistent with the proposal that conserved histidine and tyrosine residues 
play important catalytic roles.  Superposition of the ternary Naa50p complex with the 
peptide-bound Gcn5 histone acetyltransferase (HAT) reveals that the two enzymes share 
a GNAT (Gcn5-related N-acetyltransferase) fold, but differ in their respective substrate 
binding grooves such that Naa50p can accommodate only an α-amino substrate and not a 
side-chain lysine substrate that is acetylated by lysine acetyltransferase (KAT) enzymes 
such as Gcn5 (Poux et al., 2002; Rojas et al., 1999).  The structure of the ternary Naa50p 
complex also provides the first molecular scaffold for the design of NAT specific small 
molecule inhibitors with possible therapeutic applications. 
 
2.2  Results 
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2.2.1  Naa50p shows a GNAT fold with a more constricted protein substrate-binding site   
Crystals of the Naa50p•CoA•substrate peptide ternary complex formed in the 
space group P21 with three molecules in the asymmetric unit and diffracted to a 2.75Å 
resolution limit.  The structure was refined to an Rfree/Rwork of 19.0/25.4% with good 
stereochemistry and 96.9% of the residues in the favored region of the Ramachandran 
plot (Table 2.1).  The structure reveals a mixed α/β-fold with a conserved AcCoA binding 
core region composed of one α-helix (α3) and three β-strands (β2- β4) as seen in Figure 
2.1A.  This motif is characteristic of the GCN5-related histone N-acetyltransferases 
(GNATs) and allows us to confidently place Naa50p into this family of enzymes 
(Neuwald and Landsman, 1997).  Indeed, Naa50p superimposes well with the HAT 
domain of Gcn5 with an RMS deviation of Cα atoms of 4.1 Å (Figure 2.1B).  In addition 
to a high degree of superposition within the core domain, the entire β-sheet that cuts 
through the center of the structure (β1-β5 and β7) and the α1-turn-α2 that flanks one side 
of the protein substrate-binding site superimpose well (Figure 2.1B).  The greatest 
regions of divergence between the two proteins map to C-terminal segments of the two 
proteins that flank the opposing side of the respective protein substrate-binding site, 
which maps to an unconserved region in the GNAT superfamily of proteins (Neuwald 
and Landsman, 1997; Trievel et al., 1999).  In the case of Gcn5, this region forms a loop-
helix-loop-strand motif that facilitates the formation of a relatively wide protein substrate 
binding site, while in the case of Naa50p, this regions forms a β-hairpin (β6-loop-β7) 
containing a relatively long 14-residue loop that blocks off part of the protein substrate 
binding site that is otherwise accessible in Gcn5 (Figure 2.1B and 2.2A).  
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In addition to well ordered electron density for the entire CoA molecule, we 
observed strong electron density in the Fo-Fc map corresponding to the first 4 residues of 
the 10-residue peptide that was used for the crystal structure (Figure 2.1A and 2.2B).  
Following refinement, side chain density was visible for the first two residues of the 
peptide while backbone density could be traced to the fourth residue (Figure 2.1A).  This 
correlates with the contacts formed between the peptide and the enzyme in the crystal 
structure (Figure 2.2B and 2.2C).  Hydrogen bonding can be observed throughout the 
backbone for the first two residues and the Met
1
 and Leu
2
 side chains both sit in 
hydrophobic pockets that appear to be tailored for these residues (Figure 2.2B and 2.2C).  
There are no substantial interactions beyond the leucine backbone carbonyl group seen in 
the structure.  The overall thermal B-factor of the peptide is 73.9 Å
2
, which is high in 
relation to the overall thermal B-factor of the protein (55 Å
2
).  This discrepancy can be 
accounted for by the skewed nature of the B-factors of the individual residues of the 
peptide.  The Met
1
 has a B-factor of 62 Å
2
 and this value increases for each residue of the 
peptide that extends out of the binding pocket, with the Pro
4
 B-factor reaching 93 Å
2
.  For 
comparison, the atoms of CoA have an average B-factor of 50 Å
2
. Superposition of the 
ternary complex with the Naa50p•AcCoA binary complex (PDB code: 2OB0) shows no 
significant structural rearrangement upon substrate peptide binding (Figure 2.3), further 
revealing that Naa50p does not undergo significant structural change upon protein 
substrate binding.  
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Table 2.1  Data collection and refinement statistics for the Naa50p•CoA•peptide 
complex. 
  
Values in parentheses are for the highest resolution 
shell.  Rfree was calculated using 10% of the 
reflection data chosen randomly and omitted at the 
start of refinement. 
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Figure 2.1  Overall structure of the ternary Naa50p•CoA•peptide complex. (caption 
on following page) 
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Figure 2.1 (continued) (A) Structure of the ternary complex showing Naa50p in teal 
cartoon, Coenzyme A in magenta stick with C, N and S atoms in CPK coloring and 
substrate peptide in yellow stick with C, N and S atoms in CPK coloring.  Substrate 
peptide electron density obtained from a composite omit map (blue) is shown contoured 
to 1.5σ.  (B) Superposition of the Naa50p ternary complex with the ternary Gcn5 HAT. 
The Gcn5 enzyme and accompanying substrate peptide (orange) are shown in cartoon 
format.  The substrate peptides for each enzyme are shown as thicker cartoons for clarity. 
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Figure 2.2  Naa50p interaction with the substrate peptide.  (caption on following 
page) 
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Figure 2.2 (continued) (A) Surface of Naa50p highlighting the peptide substrate binding 
site with the peptide shown in stick representation with the same color-coding as in 
Figure 1.1A.  (B) A ChemDraw representation summarizing all the interactions between 
Naa50p and peptide. Hydrogen bonding interactions are denoted with dotted lines and 
van der Waals interactions are depicted with archs. (C) A stereo diagram of Naa50p 
interactions with substrate peptide.  Protein residues that make peptide interactions are 
highlighted.  The His112 side chain has been omitted for clarity.  Substrate peptide 
resides are labeled with yellow numbers corresponding to their sequential order.    (D) 
Sequence alignment of Naa50p orthologues from several species. The names of the 
orthologs are abbreviated as follows: Atha, Arabidopsis thaliana;  Odio, Oikopleura 
dioica;  Ptri, Populus trichocarpa;  Smoe, Selaginella moellendorffii;  Vvin, Vitis 
vinifera.  For comparison, two Naa10p orthologues are also shown. Spom, is 
Schizosaccharomyces pombe.  Numbering and secondary structure elements for Naa50p 
are indicated above the Naa50p sequence. Residues of Naa50p that contact the peptide 
backbone (+), Met
1
 (), Leu2 () and catalytic residues (*) are highlighted with the 
indicated symbols above the Naa50p sequence. 
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Figure 2.3  Naa50p•AcCoA versus Naa50p•CoA•peptide.  Superposition of the ternary 
Naa50pCoApeptide complex reported here (aqua) with the binary Naa50pAcCoA 
complex (pink) (PDB ID:  2OB0) revealing no significant structural rearrangement upon 
substrate peptide binding.  The AcCoA of the binary complex has been removed for 
clarity. 
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2.2.2  The Naa50p protein substrate binding site is ideally suited to accommodate an -
amino group of an N-terminal Met- peptide 
The amino-terminal peptide substrate points into the protein active site with the 
backbone roughly perpendicular to the central -sheet and parallel to the pantothenate 
arm of the CoA (Figure 2.1A and 2.2A).  The peptide is anchored to the protein through a 
series of hydrogen bonds between the side chains of Tyr31 and Tyr139 and the backbone 
carbonyl atoms of Met75 and His112
 
 (Figure 2.2C).  The amino-terminal methionine 
residue sits in a hydrophobic pocket composed of Phe27, Pro28 and Val29 from the 1-
2 loop and Tyr139 and Ile142 from the 7 hairpin loop, which each make van der 
Waals contacts to Met
1
 of the peptide.  The Leu
2
 residue also sits in a hydrophobic pocket 
formed by Tyr31, Phe35 from the 1-2 loop segment, Tyr138 from the 6-7 hairpin 
loop and Tyr 73 and Met 75 from the 4 strand (Figure 2.2C).  There are also hydrophilic 
groups in the vicinity of Leu
2
 such as the hydroxyls of tyrosines 73 and 138 and the 
guanidinium group of Arg62 (Figure 2.2C), which provides an explanation for the ability 
of Naa50p to acetylate a substrate with a hydrophilic residue at the second position. 
 Consistent with the importance of the amino acid composition of the amino-
terminal side chain-binding pocket, each of these residues is highly conserved within the 
Naa50p orthologues from other species (Figure 2.2D).  In particular, the residues that 
contact the peptide backbone (Tyr31, Met75, His112 and Tyr139) and Met
1
 (Phe27, 
Pro28, Val29, Tyr139 and Ile142) are strictly conserved and residues that contact Leu
2
 
(Tyr31, Phe35, Tyr73, Met75 and Tyr138) are strictly or highly conserved (Figure 2.2D). 
   32 
To directly establish the functional importance of Naa50p residues that appear to 
make important peptide substrate contacts in the crystal structure we targeted several of 
these residues for mutagenesis followed by enzymatic characterization of the mutant 
proteins.  Each mutated residue was changed to alanine and the catalytic efficiency of 
each mutant was determined and compared to the wild-type protein.  Each mutant was 
purified to homogeneity and exhibited gel filtration chromatography elution profiles 
identical to that of the wild type construct.  To further confirm that the mutant proteins 
were folded properly they were subjected to circular dichroism experiments, each 
revealing a similar spectrum to the wild-type protein (data not shown).  Notably, each of 
the mutant proteins showed defects in catalytic efficiency, with most of the mutant 
proteins showing no detectable activity (Figure 2.4 and Table 2.2).  Of the residues that 
contact the peptide backbone, Tyr31, His112 and Tyr139, were mutated and each of these 
mutants showed no detectable activity, arguing for the importance of these residues for 
backbone interaction, although Tyr31 also participates in Leu
2
 peptide contact and 
His112 likely participates directly in catalysis, as will be described below (Figure 2.4 and 
Table 2.2).   Of the residues that contact Met
1
 of the peptide, the Phe27 mutant showed 
no detectable activity, while the Pro28 and Val29 mutants showed at least an 85% 
reduction in activity.  The Tyr139 mutant showed no detectable activity and Ile142 
retained about 40% activity (Figure 2.4 and Table 2.2).   Mutants of Leu
2
 peptide contact 
residues Tyr31, Phe35 and Tyr73 each showed no detectable activity (Figure 2.4 and 
Table 2.2).  Taken together, the structure-based mutagenesis is consistent with the 
functional importance of the protein-peptide substrate interactions observed in the crystal 
structure. 
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Figure 2.4  Catalytic efficiency of Naa50p and mutant proteins.  Four data points 
were collected for each enzyme in triplicate.  The straight line formed by these four data 
points crosses through the origin, indicative of the fact that their slope can be used to 
calculate catalytic efficiency. 
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Table 2.2  Catalytic efficiency of Naa50p wild type enzyme and mutants.  
 
 
*Mutants that did not yield detectable 
activity at 2.0 mM substrate peptide and a 
saturating amount of AcCoA are labeled 
ND. 
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2.2.3  Tyr73 and His112 likely play catalytic roles through an ordered water molecule 
Analysis of the Naa50p active site reveals that only two residues are in position to 
function in catalysis, Tyr73 and His112 (Figure 2.5A).  Although the functional groups of 
these residues could participate in proton extraction of the amino nitrogen substrate, the 
hydroxyl of Tyr73 and the imidazole nitrogen of His112 are too far for direct proton 
extraction.  To potentially circumvent this issue, a well ordered water molecule, with a B-
factor of 48 Å
2
, is in a position to mediate proton abstraction.  This molecule is held in 
place via hydrogen bonds with the peptide amino-terminal α-amine group, and the 
backbone carbonyl and nitrogen of Ile74 and His112, respectively (Figure 2.5A).  
Supporting the role of such a water molecule, the GNAT histone acetyltransferase Gcn5 
has been shown to employ a glutamate residue to mediate proton abstraction from the 
substrate peptide through a well-ordered water molecule (Rojas et al., 1999).  An active 
site alignment of these two proteins shows that Tyr73 of Naa50p aligns very well with 
the catalytic Glu122 of Gcn5 (Figure 2.5B), which supports a role of Tyr73 of Naa50p as 
participating in catalysis (Tanner et al., 1999).  Further supporting the catalytic roles of 
Tyr73 and His112 of Naa50p is a superposition of the Naa50p active site with the active 
site of the bacterial NAT protein RimI (Figure 2.5B) (Vetting et al., 2008).  This 
superposition illustrates that the catalytic glutamate general base residue of RimI sits 
roughly midway between Tyr73 and His112 of Naa50p and that RimI also contains a 
well-ordered water molecule in a similar position to the corresponding water molecule of 
Naa50p.   
To directly probe the functional importance of Naa50p Tyr73 and His112, we 
mutated these residues individually to both alanine and phenylalanine, purified these 
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proteins to homogeneity, confirmed that these proteins were properly folded by circular 
dichroism and analyzed their catalytic properties.   As can be seen in Table 2.2, each of 
the mutants showed background levels of catalytic activity consistent with a role for 
Tyr73 and His112 in catalysis by Naa50p, although other non-catalytic effects of 
mutating Tyr73 and His112 cannot be ruled out.  We also carried out a pH-rate profile of 
wild-type Naa50p from pH 8.0 to 6.0, the most acidic environment at which activity 
could still be measured (Figure 2.5C).  As can be seen in Figure 2.5C, the wild-type 
enzyme shows optimal activity at above pH 7.5 and the kcat decreases about 3-fold when 
the pH is decreased to 6.0.  The inflection point at ~pH 7.0 could represent the pKa of the 
catalytic base or that of the substrate α-amino group in the active site.  While a pH of 7.0 
is reasonable for the imidazole side chain, one would expect a more drastic catalytic 
effect once the side chain is fully protonated if the histidine was the only residue that 
participated in proton abstraction.  Taken together, this data is consistent with the 
proposal that Tyr73 and His112 cooperate in functioning as general bases for catalysis 
that proceeds through the ordered water molecule observed in the crystal structure.  
Tyr73 and His112 do not appear to be in proper position in the current structure to act as 
general acids for reprotonation of the CoA leaving group, although it is possible that one 
of these residues or a different protein residue might swing into place to play this role 
following the acetyl-transfer.  
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Figure 2.5  The Naa50p active site.  (A) Detailed view of the active site highlighting an 
ordered water molecule that plays a putative catalytic role along with Tyr73 and His112 
in proton extraction from the α-amino group of the peptide substrate. Hydrogen bonds are 
depicted with a gray dashed line. Substrate peptide resides are labeled with yellow 
numbers corresponding to their sequential order.  (B) Superposition of the Naa50p active 
site with the active sites of bacterial RimI and the Gcn5 HAT. RimI and Gcn5 substrates, 
catalytic residues and water molecule are shown in pink and orange, respectively.  (C) 
pH-rate profile for wild type Naa50p.  See the methods section for details. 
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2.2.4  Comparison to the Gcn5 ternary complex suggests why Naa50p prefers N-amino 
vs. side chain lysine substrates 
While there have been several reports of NATs performing internal lysine 
acetylation, it is clear that the process is very slow in relation to the observed α-amino 
acetyltransferase activity (Evjenth et al., 2009; Seo et al., 2010).  To better understand the 
structural basis for Naa50p preference for N-terminal acetylation, we superimposed the 
ternary Naa50p complex with the tGCN5•CoA•H3 peptide complex in order to identify 
key differences in substrate peptide binding motifs (PDB ID:  1QSN) (Rojas et al., 1999). 
As noted earlier, the two structures share a similar overall fold with the most pronounced 
differences mapping to the C-terminal segment of the proteins and particularly to the β6-
β7 loop flanking one side of the protein peptide binding site (Figure 2.6A).  As a result of 
this difference, one side of the Naa50p protein substrate-binding site is constricted such 
that a lysine side-chain containing peptide segment cannot sit across the substrate 
binding-groove (Figure 2.6B).   Indeed, Ile142 of the β6-β7 loop makes van der Waals 
interactions with Pro28 and Val29 of the α1-α2 loop across the binding groove and 
Arg141 also sits across the binding groove (Figure 2.6A).  Since the more constricted 
Naa50p substrate-binding site cannot easily accommodate a peptide sitting across the 
substrate-binding site, it must accommodate a peptide substrate that enters the active site 
in a different orientation.  This is consistent with the binding mode of the amino-terminal 
peptide that enters the active site from the accessible end of the peptide binding groove 
and at roughly a 90° angle relative to the histone H3 peptide bound to Gcn5 (Figure 
2.1B).  Residues that participate in constricting one end of the Naa50p binding groove, 
Pro28, Val29 and Ile142, also participate in amino-terminal peptide binding (Figure 
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2.2C).   The unique features that differentiate Naa50p from Gcn5 are conserved in the 
RimI structure (Figure 2.6C) and we extrapolate that they are conserved throughout the 
NATs to mediate amino-terminal acetylation specificity. 
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Figure 2.6  Structural comparison with other acetyltransferases.  (A) Structural 
alignment of Naa50p with the Gcn5 HAT.  The proteins are shown in cartoon with the 
peptide substrates shown in stick figure with CPK coloring. The CoA molecule from 
Naa50p is also shown in stick figure. The zoom view (rotated 30° clockwise on the y-
axis) shows a stereo image that includes the position of several side chains in the Naa50p 
substrate binding loops.  (B) Surface representation of Naa50p with a stick model of the 
Gcn5 substrate peptide docked into the Naa50p peptide-binding site.  (C) Structural 
alignment of Naa50p with the bacterial NAT RimI.  The Rim protein is shown in purple 
cartoon with the associated bisubstrate inhibitor shown in purple stick figure with CPK 
coloring. 
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2.3  Discussion 
Despite its biological importance, the process of amino-terminal protein 
acetylation remains relatively poorly understood.  In contrast, histone acetyltransferases 
(HATs) that modify side-chain lysine residues have been extensively characterized at 
both the biochemical and structural levels, and this understanding has led to the 
development of HAT specific inhibitors (Bowers et al., 2010; Furdas et al., 2011; Wu et 
al., 2011).  The ternary structure of Naa50p bound to CoA and a peptide fragment of its 
native substrate reported here now provides the first molecular insights into the 
mechanism of substrate binding and possibly also catalysis used by this class of enzymes 
and provides a molecular scaffold for the design of NAT specific inhibitors. 
 The stringent requirement of Naa50p for a substrate containing an amino-terminal 
methionine is well explained by the structure and accompanying mutagenesis and 
enzymology studies.  The enzyme uses a hydrophobic pocket that forms van der Waals 
contacts with the methionine residue, which prevents the enzyme from interacting with 
all other potential amino-terminal residues.  BLAST alignments reveal that these residues 
are highly conserved among Naa50p homologues but not in Naa10p orthologues (Figure 
2.2D).  It is likely that the corresponding residues in Naa10p are optimized to be more 
tolerant of amino acid variability in this position.  Notably, most of the Naa50p residues 
that mediate peptide backbone interactions (Tyr31, His112 and Tyr139) are conserved 
with the Naa10p proteins, suggesting that the binding mode of the amino-terminal protein 
segment to the Naa10p proteins might be similar to that of Naa50p.  The interactions 
between Naa50p and peptide residues C-terminal to Met
1
 are less extensive, which allows 
for more flexibility in substrate residue identity at these positions (Figure 2.2C).  
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Previous studies show that Naa50p activity is effected by the first four residues of the 
substrate peptide sequence (Evjenth et al., 2009).  Here, we have been able to provide an 
explanation for the ability of the enzyme to accommodate both hydrophobic and 
hydrophilic residues at the second amino acid position of the substrate.  The third and 
fourth substrate residues in the structure presented here are partially disordered and so it 
is difficult to draw conclusions regarding their role in substrate binding from the 
structure.  A point mutation screen shows that conservative mutations in the third and 
fourth positions are tolerated quite well, with the most detrimental mutations at these 
positions exhibiting only a 5-fold reduction in Km and a modest effect on kcat (Evjenth et 
al., 2009).  This is in contrast to the more drastic effects on mutations of Met
1
 or Leu
2
. 
 The GNAT family of enzymes has been shown to employ a variety of different 
chemical strategies to perform protein acetylation.  For example, the Gcn5/PCAF family 
of HATs uses a conserved glutamic acid residue to serve as a general base for a ternary 
complex mechanism (Clements et al., 1999; Langer et al., 2001), the p300/CBP family 
does not employ a dedicated general base for catalysis but likely uses a tyrosine residue 
as a general acid to mediate a Theorell-Chance catalytic mechanism (Liu et al., 2008).  
Interestingly, the MYST family of histone acetyltransferases use a ping-pong mechanism 
in which the glutamate general base first catalyzes the acetyl-transfer to a conserved 
cysteine residue and then catalyzes a second deprotonation step to facilitate transfer of 
the same acetyl group to a substrate lysine residue (Holbert et al., 2007; Yan et al., 2002; 
Yuan et al., 2012).  In addition, the small molecule acetyltransferase, serotonin 
acetyltransferase, employs two histidine residues to act as general bases for catalysis, and 
it is likely that the archaeal protein acetyltransferase (PAT) enzymes use multiple 
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residues as bases in its mechanism as well (Brent et al., 2009; Hickman et al., 1999; 
Scheibner et al., 2002).  In light of the varied ways in which acetyltransferase enzymes 
carry out chemistry, it is not surprising that Naa50p appears to use yet another chemical 
strategy that likely involves histidine (His112) and tyrosine (Tyr73) general base 
residues, at least one of which might function as a general acid as well (Figure 2.5A).    
 It is also of note that the in vitro catalytic parameters derived in this study are 
inefficient relative to other acetyltransferases (which are measured on a sec
-1
 scale).  The 
slower rate observed for the recombinant Naa50p may be a consequence of the absence 
of the Naa15p or Naa10p subunits, which might function to elevate the catalytic rate.  It 
is also possible that there exists a subset of unidentified Naa50p substrates that the 
enzyme is able to acetylate with a more biologically relevant enzymatic rate. 
 Finally, this study represents the first description of the molecular details that 
distinguish the substrate binding modes between the amino-terminal and side-chain lysine 
protein acetyltransferases. There appear to be several features of the Naa50p protein 
substrate binding site that center around an extended β6-β7 hairpin loop, which plays a 
particularly important role in biasing the specificity of the NAT proteins for amino-
terminal α-amino groups.  Our results are therefore in agreement with previous studies 
that have shown that Naa50p is a very inefficient lysine side-chain acetyltransferase 
(Evjenth et al., 2009).  We also anticipate that the ternary Naa50p scaffold provided here, 
along with the distinguishing features between NATs and KATs, may lead to the 
development of NAT specific inhibitors that might have therapeutic applications.  
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2.4  Materials and methods 
2.4.1  Naa50p expression and purification 
A pETM-GST vector (G. Stier, EMBL, Germany) containing DNA encoding the 
full length human Naa50p (1-169) fused to GST through a tobacco etch virus (TEV) 
protease cleavable site was transformed into BL21 (DE3) cells.  The transformed cells 
were cultured at 37°C until the cell OD600 reached ~0.7, induced for protein expression 
with 0.5mM isopropyl 1-thio-β-D-galactopyranoside and grown overnight at 18°C.  Cells 
were isolated by centrifugation and lysed by sonication in a lysis buffer containing 25 
mM HEPES, pH 7.5, 100 mM NaCl, and 10mM 2-mercaptoethanol.  The supernatant 
was isolated and passed over GST-binding resin (Clonetech).  Unbound proteins were 
washed off the resin with lysis buffer and TEV protease was added directly to the resin 
and allowed to incubate overnight at room temperature.  Untagged Naa50p was washed 
off the resin with lysis buffer, collected, dialyzed into a buffer containing 25 mM 
HEPES, pH 7.5, 50 mM NaCl, and 10 mM 2-mercaptoethanol and bound to a 5 mL 
HiTrap SP ion exchange column (GE Healthcare).  The protein was eluted in the same 
buffer using a salt gradient of 50-750 mM NaCl and further purified to homogeneity 
using a Superdex 75 gel filtration column (GE Healthcare) in a storage buffer containing 
25mM HEPES, pH 7.5, 100 mM NaCl, and 10 mM dithiothreitol.  Peak fractions 
containing protein that was greater than 95% pure as judged by SDS-PAGE was 
concentrated to ~ 12 mg/ml using a 10 kDa protein concentrator (Millipore) and stored at 
–70°C until further use. All protein mutants were generated using the QuikChange 
protocol from Stratagene (Braman et al., 1996).  Protein harboring point mutations was 
obtained following the expression and purification protocols described above. 
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2.4.2  Crystallization and data collection 
The peptides and Coenzyme A used in crystallization were purchased from 
GenScript and Sigma-Aldrich, respectively. The Naa50p•CoA•peptide ternary complex 
was prepared for crystallization by mixing in a 1:3:3 molar ratio, respectively.  The 
length of the substrate peptide was varied between 7-20 amino acids in crystallization 
trials.  The protein concentration used in crystallization was 12 mg/mL and the peptide 
that produced the best diffracting crystals was a 10-mer with the sequence 
MLGPEGGRWG. Crystals of the ternary Naa50p•CoA•peptide complex were grown by 
hanging drop vapor diffusion at 20°C over 1-3 days against a reservoir solution 
containing 16% PEG 8000, 20% glycerol and 40 mM potassium phosphate (monobasic), 
pH 5.0.  Crystals were transferred to a harvest solution containing well solution 
supplemented with 25% glycerol prior to flash freezing in liquid nitrogen.  Data was 
collected at Beamline X6A at the National Synchrotron Light Source (Brookhaven 
National Labs) and processed using HKL2000 (Otwinowski and Minor, 1997).   
 
2.4.3  Structure determination and refinement 
The structure of the ternary Naa50p•CoA•peptide complex was determined by 
molecular replacement with Phaser in the CCP4 suite of programs using the Naa50p•CoA 
binary complex (PDB ID: 2PSW) as a search model (McCoy et al., 2007).  Solvent 
molecules and CoA were excluded from the search model.  Structure refinement was 
performed by initially applying 3-fold non-crystallographic symmetry (NCS) and running 
Phenix.Refine with Group ADPs (atomic displacement parameters) for the initial cycles 
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(Adams et al., 2010).  Subsequently, CoA and substrate peptide were built into the 
resulting Fo-Fc electron density map and additional refinement was performed manually 
using the molecular graphics program Coot (Emsley and Cowtan, 2004).  In advanced 
stages of refinement, NCS restraints were released, individual ADPs were refined and 
solvent was added.  The final model was checked for errors against a composite omit map 
generated in CNS (Brunger et al., 1998).  Refinement statistics can be found in Table 1.  
The final model and structure factors were submitted to the Protein Data Bank with PDB 
ID 3TFY. 
 
2.4.4  Acetyltransferase activity assays 
Naa50p acetyltransferase assays were carried out with 100 nM untagged, full 
length enzyme at 37°C for 40 minutes in 100 mM Tris, pH 8.0 and 50 mM NaCl unless 
stated otherwise.  A saturating amount of AcCoA (300 µM) was used in all enzymatic 
reactions and substrate peptide (
+
NH3-MLGPEGGRWGRPVGRRRRP-COO
-
, 
GenScript) concentration was varied to determine steady state catalytic parameters.  In 
the assay, radiolabeled [
14
C] Acetyl coenzyme A (4 mCi/mmol, PerkinElmer) was mixed 
with substrate peptide and allowed to incubate with enzyme in a 25 µL reaction volume.  
To quench the reaction, 20 µL of the reaction mixture was added to P81 paper discs 
(Whatman) and the paper discs were immediately placed into wash buffer.  Washes were 
then carried out three times in 10 mM HEPES, pH 7.5, with each wash lasting 5 minutes, 
to remove unreacted AcCoA.  The papers were then dried with acetone, added to 4mL of 
scintillation fluid, and the signal was measured using a Packard Tri-Carb 1500 liquid 
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scintillation analyzer.  Background control reactions were performed in the absence of 
enzyme.  Reactions were also performed in the absence of substrate peptide to ensure that 
any possible signal due to autoacetylation was negligible.  Substrate peptide Km and Vmax 
parameters were derived by titrating substrate peptide at 8 different concentrations 
ranging from 100µM-1500 µM in the presence of 300 µM AcCoA.  Complications 
caused by TFA from the addition of high concentrations of substrate peptide prevented 
point mutant catalytic assays from reaching a saturating amount of peptide, and so we 
instead analyzed the catalytic efficiency (kcat/Km) of these mutants.  By keeping the 
substrate concentration far below Km, we were able to plot velocity vs. [peptide] and use 
the slope of the resulting line to obtain kcat/Km values for several of these mutants based 
on the equation:  v=(kcat/Km) [E][S].  These results allowed us to quantitatively compare 
the catalytic efficiencies of each mutant to the wild type enzyme.  The AcCoA Km value 
was determined by titrating a range of AcCoA concentrations (25 µM-500 µM) into a 
reaction containing 2.5 mM peptide in a buffer containing 50 mM NaCl and 200 mM 
Tris, pH 8.0.  The high concentration of Tris is required to counter the pH effect caused 
by TFA carried into the reaction with high concentrations of peptide.  A pH-rate profile 
was determined using a three component buffer system able to maintain constant ionic 
strength at all pH values used in the study (Tanner et al., 1999).  All reactions were 
performed in triplicate.  All radioactive count values were converted to molar units using 
a standard curve created with known concentrations of radioactive AcCoA added to 
scintillation fluid. 
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2.4.5  Materials and methods (‘Future directions’) 
 Naa50p was cloned out of the Schizosaccaromyces pombe and cloned into a 
modified pCDFDUET vector with a TEV-cleavable GST-tag.  The resulting plasmid was 
transformed into Rosetta (DE3)pLysS competent E. coli cells (Agilent), grown to an 
OD600=0.7 and induced with 0.5 mM IPTG at 16°C for ~16 hours.  Cells were isolated by 
centrifugation and lysed by sonication in a buffer containing 25 mM Tris (pH 8.0), 200 
mM NaCl, 10 mM β-ME and 0.5mM PMSF (Sigma-Aldrich).  The solution was isolated 
and passed over GST-resin (GoldBio), which was subsequently washed with > 20 column 
volumes of lysis buffer.  TEV protease was added directly to protein-bound resin for 14 
hours under gentle agitation.  The resin was then washed with 5 CV of lysis buffer to 
remove all cut protein and dialyzed into a buffer of 25mM Bis-Tris (pH 6.0), 0mM NaCl 
and 2 mM DTT for 3-8 hours and loaded onto a 5 mL HiTrap SP ion exchange column 
(GE Healthcare).  Protein was eluted from the column using a salt gradient from 0-
750mM NaCl over 30 CV in 25mM Bis-Tris and 2mM DTT.  Peak fractions were 
concentrated to ~1-2 mL (10kDa concentrator; Amicon Ultra, Millipore), mixed with 
purified NatA complex (for purification, see Chapter 3 ‘Materials and methods’) in a 4:1 
(Naa50p:NatA complex) molar ratio, and loaded onto an s200prep gel filtration column 
(GE Healthcare) that was pre-equilibrated in a buffer containing 25 mM HEPES (pH 
7.0), 200 mM NaCl and 2 mM DTT.  The elution profile shows 2 peaks, the first 
corresponding to the NatANaa50p complex and the second corresponding to excess 
Naa50p.  The NatANaa50p complex was pooled and concentrated to 10 mg/mL as 
measured by UV280 absorbance (extinction coefficient = 115,000), for crystallization 
trials. 
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NatANaa50p was mixed with 6-fold molar excess of AcCoA and crystal hits 
were obtained at 20°C using hanging drop vapor diffusion in a well condition containing 
18% PEG 3350 (Hampton Research) and 0.2 M sodium citrate tribasic dihydrate 
(Hampton Research).  To optimize, concentrations of protein and PEG 3350 were varied 
and several different buffers at various pH values were added to the well.  The best 
crystals show diffraction to ~15 Å at NSLS and the data cannot be indexed.   
For GST pull-downs assays, GST-Naa50p was left immobilized on the resin after 
the wash step in the purification described above, and NatA or Naa10p (purifications 
described in Chapter 3 ‘Materials and methods’) equilibrated in lysis buffer were passed 
over the column five times.  The column was then eluted using 5 CV of lysis buffer 
supplemented with 10 mM glutathione.  Control experiments were performed using GST-
bound resin (GST protein was a gift from Daniel B.P. Ricketts).   
 
2.5  Future directions and preliminary NatANaa50p complex studies 
 The association between Naa50p and the NatA complex is not well understood.  
Naa10p and Naa15p immunoprecipitation experiments have been used to show that the 
NatA complex is stoichiometrically associated with the Naa50p enzyme in both yeast and 
human cell lysates (Arnesen et al., 2006a; Gautschi et al., 2003).  While these reports 
suggest that Naa50p interacts with the Naa15p auxiliary subunit, the potential for Naa10p 
to play a role in this interaction cannot be ruled out.  It is also unclear why the 
independently active Naa50p enzyme associates with the NatA complex.  Preliminary 
experiments (waiver:  experiments performed by my rotating students) suggest that 
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complex formation has no effect on the kcat or Km exhibited by the Naa50p enzyme 
towards its biologically relevant substrate.  It is possible that Naa50p uses complex 
formation solely for recruitment to the ribosome or that complex formation is required to 
activate Naa50p towards a subset of substrates that has not yet been identified.  To probe 
these outstanding questions, we have set out to biochemically and structurally 
characterize the Naa50pNatA complex.   
Our structural characterization of NatA shows that the enzyme wraps completely 
around the Naa10p subunit and no unambiguous secondary catalytic subunit-binding 
interface can be identified.  To verify that Naa50p indeed interacts with the NatA 
complex and does not compete with Naa10p for binding to Naa15p, we mixed untagged 
NatA with immobilized GST-Naa50p and showed that GST-Naa50p is able to pull down 
both the Naa10p and the Naa15p subunit (Figure 2.7A).  Additionally, we were able to 
show that GST-Naa50p is unable to pull down monomeric Naa10p (Figure 2.7B)
1
.  This 
series of pull-downs confirms that the Naa50p is not competing with the Naa10p subunit 
for binding to Naa15p and verifies that there is an independent Naa50p binding surface 
on the NatA complex.  While we can conclude that Naa50p is not interacting with 
monomeric Naa10p in vitro, we cannot conclude that this subunit is completely 
uninvolved in the Naa50p interaction in the context of the NatA complex due to our 
observation that the Naa15p subunit alters the fold of the Naa10p subunit.  To further 
characterize this interaction, we have also crystallized the Naa50pNatA complex for x-
                                                          
1
 An identical experiment with Naa15p could not be performed due to instability of this 
subunit in its monomeric form. 
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ray diffraction studies (Figure 2.8A). Currently, these crystals diffract poorly and 
optimization of protein constructs and crystallization conditions is ongoing (Figure 2.8B). 
Ideally, this study would be used to guide mutagenesis targeted at disrupting the 
Naa50pNatA interface.  We could use these mutants to further analyze the effect of 
complex formation on catalysis and use in vivo experiments to determine the role of 
complex formation in co-translational acetylation by this enzyme.  
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Figure 2.7  Naa50p interacts with the NatA complex in vitro.  (A) GST-tagged Naa50p 
mixed with the untagged NatA complex and purified using GST resin. (B)  GST-tagged 
Naa50p mixed with untagged Naa10p and purified using GST resin.  (C)  GST mixed 
with untagged NatA complex and purified using GST resin. 
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Figure 2.8  NatA•Naa50p crystals and preliminary diffraction.  (A)  Crystals of the 
NatANaa50p complex.  (B)  Preliminary diffraction pattern of the crystals shown in (A). 
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CHAPTER 3 
 
The molecular basis for amino-terminal acetylation by the NatA complex 
 
 
 
 
 
 
 
 
 
 
 
 
 
Liszczak et al., 2013 (submitted) 
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3.1  Introduction and summary of conclusions 
 Despite the fact that NATs as well as many other lysine side-chain 
acetyltransferases require binding partners for optimal catalytic activity, no 
acetyltransferase has been structurally characterized in the presence of its activating 
partner (Iizuka and Stillman, 1999; Parthun et al., 1996; Sutton et al., 2003).  
Furthermore, there is no structural data for any integral subunit of a NAT complex and 
the mechanism of catalysis employed by these enzymes remains completely 
uncharacterized.  In this study we set out to determine the molecular basis for substrate 
binding, acetylation specificity and mode of catalysis of the NatA complex, and to 
determine the role of the auxiliary subunit in these activities.   
Here, we report the x-ray crystal structure of the active 100 kDa holo-NatA 
complex from Schizosaccharomyces pombe in the absence and presence of a bisubstrate 
peptide-CoA conjugate inhibitor at 3.15 Å and 2.60 Å resolution, respectively, as well as 
the structure of the uncomplexed Naa10p catalytic subunit at 2.00 Å resolution.  The 
Naa15p auxiliary subunit contains 13 TPR motifs and adopts a ring-like topology that 
wraps completely around the Naa10p subunit.  This interaction alters the Naa10p active 
site for substrate-specific acetylation such that a key catalytic residue would be displaced 
upon interaction with a non-cognate substrate peptide.  The bisubstrate peptide-CoA 
conjugate NatA inhibitor that we developed also lays the foundation for the development 
of potent and selective NatA therapeutics.  These studies have important implications for 
understanding the activity and regulation of other NAT complexes and for how 
regulatory subunits modulate the activity of the broader family of protein 
acetyltransferases. 
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3.2  Results 
3.2.1  Overall structure of the NatA complex 
In an attempt to prepare the NatA complex for x-ray structure determination, we 
overexpressed the human complex in Sf9 infected insect cells and the othologous proteins 
from Saccharomyces cerevisiae and Schizosaccharomyces pombe in insect cells and 
bacteria, respectively.  We found that coexpression of the Schizosaccharomyces pombe 
full-length Naa15p subunit (residues 1-729) with a C-terminal truncation construct of the 
Naa10p subunit (residues 1-156 out of 177 total residues) produced a soluble, active, 
heterodimeric complex that could be purified to homogeneity and crystallized for use in 
structural studies.   Crystals of this NatA complex were formed in the presence of AcCoA 
in the P1 space group with 4 heterodimers in the asymmetric unit and the structure was 
determined using multiwavelength anomalous diffraction with a combination of a 
K2PtBr4 heavy atom soaked crystal and selenomethionine-derivatized protein (Table 3.1).  
The dataset was refined to Rwork and Rfree values of 22.4% and 25.9%, respectively. 
The structure of the NatA complex reveals that the auxiliary Naa15p subunit is 
composed of 37 α-helices ranging from 8 to 32 residues in length, among which 13 well 
conserved helical bundle tetratricopeptide repeat (TPR) motifs can be identified, which 
are often employed for protein-protein interactions (Figures 3.1 and 3.2).  While a 
number of these TPR-helices are involved in interaction with Naa10p, we suspect that the 
additional TPR motifs are important for interaction with other NatA binding partners 
such as the ribosome, NatE and the HYPK chaperone (Arnesen et al., 2010; Gautschi et 
al., 2003).  The Naa15p helices arrange themselves into a ring-like tertiary structure that 
wraps completely around the Naa10p subunit, burying a total of 3,520 Å
2
 of the solvent 
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accessible surface area of the enzyme (Figure 3.3A and 3.3B).   This fold is reminiscent 
of the importin-β structure, which employs 19 tandem HEAT repeats to form a solenoid 
tertiary structure that surrounds its binding partner, importin-α (Cingolani et al., 1999).  
Indeed, it appears that Naa15p stability depends on the binding of Naa10p.  This is 
consistent with the observation that recombinant Naa15p undergoes significant 
degradation and precipitation when purified as a monomer. 
The catalytic Naa10p subunit adopts a Gcn5-related N-acetyltransferase (GNAT) 
fold (Vetting et al., 2005) containing a central AcCoA binding region and flanking N- 
and C- terminal segments that are similar to the structure of NAA50. The most intimate 
interactions between the two proteins are made between several Naa15p helices and the 
N-terminal α1-loop-α2 segment of Naa10p (Figures 3.3C and 3.3D), where the structure 
has relatively low B-factors and is well ordered (Figures 3.4A and B).  This region 
features one large hydrophobic interface between residues that span the entire length of 
Naa10p-α2 (L28, L32, Y33, I36, W38) and several residues of Naa10p-α1 (I8 and L11) 
with residues in Naa15p-α29 (W526, F533, F536) and –α30 (L549, W552); and hydrogen 
bonds between Naa10p-K29 and Naa10p-Q15 with Naa15p-D532 and Naa15p-Q491, 
respectively.  Single point mutations in this region do not break up the complex, and have 
only modest effects on substrate binding and catalysis (Table 3.2), likely due to the 
extensiveness of the interface.  A smaller hydrophobic interface is formed between 
Naa10p-H20 with Naa15p-F449 and Naa15p-W494 and is supplemented with a hydrogen 
bond between Naa10p-N25 and Naa15p-R448.  This region of Naa15p directly stabilizes 
the position of the Naa10p-α1 helix as well as the Naa10p-α1-α2 loop and as a result is 
crucial for proper complex formation.  This is evident from the observation that alanine 
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point mutations at either Naa15p-R448 or Naa15p-F449 disrupt NatA complex 
formation.  Several additional scattered intermolecular interactions serve to supplement 
the Naa10p-Naa15p interface (Figure 3.5). 
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Table 3.1  Data collection, phasing and refinement statistics 
 
Values in parentheses are for the highest resolution data shell.  Rfree was calculated using 
5% of the reflection data and omitted at the start of refinement.  r.m.s.d., root mean 
standard deviation; DM, density modification; A.U., asymmetric unit. 
*These two chains make up the heterodimer with the lowest average B-factor in the 
AcCoA and bisubstrate inhibitor-bound complexes.  All figures were generated using 
these heterodimers. 
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Table 3.2  Catalytic parameters for wild type and mutant NatA as well as wild type 
monomeric Naa10p with various substrate peptides 
 
The kcat and Km for all catalytic assays performed are given.  Where kcat=N/A, the Km is 
greater than 2,000 μM and as a result a rate could not be calculated from our assay.  
Where kcat=N.D., activity could not be detected in our assay. 
+
All normalizations reported are relative to wild type NatA catalytic parameters 
generated with the Ser- amino-terminal substrate. 
*The AcCoA Km was calculated for these variants (WT=59±5 μM, L22A=53±6 μM). 
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Figure 3.1  TPR repeats in Naa15p.  (A) The helices that make up each TPR repeat are 
colored in alternating dark blue and light blue and the first helix of each repeat is 
numbered.  All other Naa15p helices are shown in brown cartoon format and the N and 
C-termini are labeled.  Naa10p is shown in teal cartoon format and AcCoA is shown in 
blue stick format. (B) Same as (A) but rotated 180°.  All observed TPR repeats match the 
known TPR motif divergent consensus sequence (Karpenahalli et al., 2007).
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Figure 3.2  Conservation across Naa15p subunits.  (A) The Naa15p is shown in 
surface representation with residues colored according to conservation exhibited in an 
alignment of corresponding subunits in S. pombe, H. sapiens, A. thaliana, S. cerevisiae, 
C. elegans and D. melanogaster.  The key provided indicates the level of conservation 
represented by each color.  Naa10p is shown in teal cartoon format and AcCoA is shown 
in blue stick format.  (B) Same as (A) but rotated 180°.  No unambiguous putative 
ribosomal binding surface can be identified from this conservation map. 
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Figure 3.3  The overall structure of the NatA complex bound to AcCoA. (A) The 
Naa10p (teal) and Naa15p (brown) subunits are shown in cartoon bound to AcCoA (CPK 
coloring and stick format). Only Naa15p helices that contact Naa10p are labeled.  The 
dotted brown line represents a disordered loop region in Naa15p.  The dimensions of the 
complex are 107 Å x 85 Å x 70 Å.  (B) A 90° rotation of the view in (A).  (C) A zoom 
view highlighting key residues that comprise the mostly hydrophobic interface between 
Naa10p-α1-α2 and Naa15p-α29-α30.    (D) A zoom view of the intersubunit interface at 
the C-terminal region of Naa10p-α1 and Naa15p helices. 
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Figure 3.4  Average B-factor distribution.  (caption on following page) 
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Figure 3.4 (continued) (A) The average B-factor for each helix and loop in Naa15p 
(cartoon format) is colored according to the key provided.  Naa10p is shown in teal 
cartoon format and the AcCoA is shown in blue stick format.  All visible helices from 
each subunit are labeled, as are the N and C-termini of Naa15p.  (B) Identical to (A) but 
rotated 90°.  Helices not labeled in (B) are labeled here. (C) The average B-factor for 
each helix, strand, and loop in Naa10p (cartoon format) is colored according to the key 
provided.  Naa15p is represented in brown cartoon format and AcCoA is shown in blue 
stick format.  All helices in Naa10p are labeled. (D) Identical to panel (C) but rotated 
90°.  Naa15p helices α23 though α32 have been omitted for clarity.  Only N and C-
terminal helices from Naa15p are labeled. 
*The α20-α21 loop has an average B-factor of 196 Å
2
 (see supplemental text for 
explanation). 
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Figure 3.5  Additional contacts at the Naa10p•Naa15p interface.  (caption on 
following page) 
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Figure 3.5 (continued) (A) A full view of the complex with Naa10p shown in teal 
cartoon format, Naa15p shown in brown cartoon format, and AcCoA shown in blue stick 
format.  A region in which intermolecular contacts are formed has been boxed.  
Secondary structure elements visible in the corresponding zoom view are labeled.  The N 
and C-termini of Naa15p are labeled.  (B) Identical to (A) but rotated 90°.  (C) A zoom 
view of the boxed region in (A).  Residues involved in intermolecular contacts are shown 
in stick format and all secondary structure elements are labeled.  Hydrogen bonds are 
shown with black dotted lines.  (D) A zoom view of the boxed region in (B).  Residues 
involved in intermolecular contacts are shown in stick format and all secondary structure 
elements are labeled.  Hydrogen bonds are shown with black dotted lines. 
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3.2.2  Structure of uncomplexed Naa10p subunit and the molecular basis for Naa15p 
modulation of Naa10p acetylation 
To explore the molecular basis for Naa15p modulation of Naa10p 
acetyltransferase activity, we determined the X-ray crystal structure of Naa10p in the 
absence of Naa15p, for comparison with the holo-NatA complex (Table 3.2).  The 
structure of Naa10p (residues 1-156) was determined using a combination of single 
wavelength anomalous diffraction and molecular replacement (MR), using data collected 
on a selenomethionine-derivatized Naa10p protein and NAA50 as an MR model.  An 
alignment of the complexed and uncomplexed forms of Naa10p reveals that the α1-loop-
α2 segment assumes a substantially different conformation in the presence of Naa15p 
(Figure 3.6A).  Notably, this conformational change is driven by the movement of several 
hydrophobic residues in Naa10p-α2 (L28, L32, I36), which make intramolecular 
interactions with residues in Naa10p-α1 and β3 (I8, L11, M14, Y55, Y57) in apo-Naa10p 
but shift to make alternative intermolecular interactions with helices of Naa15p in the 
NatA complex (Figure 3.6B and 3.3C). As a result of this interaction, the C-terminal 
region of the α1 helix undergoes an additional helical turn, which helps to reposition the 
α1-α2 loop.  Interestingly, docking of the apo-Naa10p structure into the corresponding 
binding pocket of Naa15p shows a clash between the Naa10p α1-loop-α2 and Naa15p-
R448 and Naa15p-F449 of α25 (Figure 3.6C), the same interface that we have shown to 
be necessary for proper complex formation (Fig. 3.3D, Table 3.2).   
As a result of the Naa15p-interaction along one side of the Naa10p-α1-loop-α2 
region, residues on the opposite side of this loop region appear to adopt a specific 
conformation that is essential for catalysis towards traditional substrates (Ala-, Cys-,  
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Gly-, Ser-, Thr-, or Val-).  Specifically, residues Naa10p-L22 and -Y26 shift about 5.0 Å 
from surface exposed positions to buried positions in the active site and Naa10p-E24 
moves by about 4.0 Å, drastically altering the landscape of the NatA active site (Figure 
3.6D).  All of these residues are well ordered in both structures (Figures 3.7A and 3.7B).  
Our comparison of the complexed and uncomplexed structures suggests that the auxiliary 
subunit induces an allosteric change in the Naa10p active site to an extent that is required 
for the mechanism of catalysis employed by the NatA complex, and likely represents an 
active NAT fold.  Consistent with this hypothesis, a backbone alignment of key active 
site elements in active Naa10p with the corresponding region in the independently active 
human NAA50 that selects a Met-Leu- amino-terminal sequence shows a high degree of 
structural conservation (RMSD of 1.52 Å).  The corresponding alignment of the 
complexed and uncomplexed forms of Naa10p shows less structural conservation, with 
an RMSD of 2.43 Å (Figure 3.6E).  
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Figure 3.6  The structure of the Naa10p monomer bound to AcCoA.  (caption on 
following page) 
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Figure 3.6 (continued) (A) A structural backbone alignment of the uncomplexed Naa10p 
monomer (silver) bound to AcCoA (gray stick format) with the active Naa10p from the 
NatA structure (teal). (B) A zoom view of the surface exposed Naa10p-α1-α2 region 
from the alignment shown in A highlights residues in these two helices that undergo a 
conformational shift upon Naa15p association.  (C) The Naa10p variants docked into the 
Naa15p subunit.  The stretch of the α1- α2 loop in the Naa10p monomer that clashes with 
Naa15p is shown in the zoom region.  Secondary structural elements are shown in 
cartoon format and have been labeled.  Key residue side chains are shown in stick format 
and have been labeled. (D) A 70° clockwise rotation of B.  The repositioning of the 
Naa10p-α1-loop- α2 upon complex formation and accompanying altered active site 
landscape are shown.  Key repositioned residues are shown in stick format. (E) A 
structural alignment of the active and inactive forms of Naa10p with hNaa50p (red) 
bound to CoA (gray stick format). 
   72 
 
Figure 3.7  Naa10p substrate binding loops with corresponding electron density.  
(A) The α1-α2 and β6-β7 loop from the Naa10pNaa15pbisubstrate inhibitor structure is 
shown with corresponding simulated annealing composite omit map contoured to 1.5σ 
(shown in blue).  Loop backbones are labeled and shown in teal cartoon format and side 
chains are labeled and shown in teal stick format.  The bisubstrate inhibitor is shown in 
orange stick format and the residues have been numerically labeled.  (B) The α1-α2 and 
β6-β7 loop from the Naa10p monomeric structure is shown with corresponding simulated 
annealing composite omit map contoured to 1.5σ.  Loop backbones are labeled and 
shown in silver cartoon format and side chains are labeled and shown in silver stick 
format.  AcCoA is shown in gray stick format. 
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3.2.3  Substrate peptide binding and NatA inhibition 
 To determine the molecular basis for substrate-specific peptide-binding by NatA, 
and in particular how, unlike most other NATs, it is able to accommodate a number of 
non-methionine amino-terminal substrates, we synthesized a bisubstrate conjugate in 
which CoA is covalently linked to a biologically relevant substrate peptide fragment with 
the sequence Ser-Ala-Ser-Glu-Ala (CoA-SASEA).  We performed inhibition studies with 
CoA-SASEA and with a control compound, acetonyl-CoA, which is a non-hydrolyzable 
AcCoA analog (Fig. 3.8A).  IC50 determinations revealed that CoA-SASEA had an IC50 
of 1.4±1.0 µM, while acetonyl-CoA had an IC50 of 380±10 µM (Fig. 3.8B).  To assess 
the specificity of this inhibitor towards NatA, we also calculated IC50 values of CoA-
SASEA and acetonyl-CoA with NAA50, a NAT that requires a substrate amino-terminal 
methionine residue.  We found that CoA-SASEA has an IC50 of 11±2 µM while acetonyl-
CoA has an IC50 of 130±12 µM (Fig. 3.8B).  With NAA50, the addition of a SASEA-
peptide portion is only able to increase the potency of acetonyl-CoA 12-fold, whereas 
with NatA this peptide addition exhibits a 271-fold increase in potency.  The greater 
potency of acetonyl-CoA with NAA50 over Naa10p can be explained by the fact that 
AcCoA binds more strongly to NAA50 (Km=27±2 µM) than it does to Naa10p (Km=59±5 
µM). The significantly higher potency of the CoA-SASEA inhibitor relative to acetonyl-
CoA towards NatA, along with the observed NatA specificity that the peptide portion 
imparts on the inhibitor, suggest that CoA-SASEA serves as a suitable transition state 
mimic for use in understanding the molecular basis for amino-terminal substrate binding 
by NatA.   
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We were able co-crystallize NatA bound to CoA-SASEA and determine its x-ray 
crystal structure using the refined NatA•AcCoA structure as a search model (Table 3.1 
and Fig. 3.9A).   The structure of the bisubstrate inhibitor-bound NatA complex reveals 
that the N-terminal Ser1 side chain makes van der Waals interactions with Naa10p 
residues L22, E24 and Y139 (Fig. 3.9B).  The Naa10p-Y139 side chain also forms a 
hydrogen bond with the Ser1 backbone carbonyl group, and Naa10p-Y26 forms a 
hydrogen-bond with the Ala2 backbone carbonyl.   
We used in vitro activity assays to kinetically characterize the wild type Naa10p 
monomer enzyme as well as wild type NatA and a series of NatA mutants (Table 3.2).  
These assays were performed in the presence of a substrate peptide with an amino-
terminal sequence identical to that of the inhibitor, a Met- amino-terminal substrate 
peptide that corresponds to the NAA50 in vivo substrate, and a substrate peptide with an 
amino-terminal Glu-Glu-Glu- sequence that matches the sequence for γ-actin, the only 
known NAA10 in vivo substrate. These studies revealed that while monomeric Naa10p is 
inactive with the Ser- amino-terminal substrate, we are able to generate catalytic 
parameters with the Glu- amino-terminal substrate (kcat=0.19 ± 0.02 sec
-1
; Km=1.72 ± 
0.25 μM) (Table 3.2).  While previous studies were able to detect acetylation of the 
amino-terminal Glu- substrate by the NatA complex (Van Damme et al., 2011a), we were 
unable to detect activity towards this substrate. In contrast, we were able to determine 
kinetic parameters for the Ser- amino-terminal substrate in the presence of a saturating 
amount of AcCoA (kcat=3.0±0.5 s
-1
 and Km=340±50 μM).  The NatA-Naa10p-L22A point 
mutation exhibited a 209-fold decrease in catalytic efficiency (kcat/Km), suggesting that 
steric alterations to the amino-terminal residue-binding pocket greatly hinders productive 
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substrate binding and catalysis (Figure 3.10 and Table 2).  Similarly, the NatA-Naa10p-
E24A mutant had no measurable activity.  The kcat of the NatA-Naa10p-E24Q was 
significantly reduced by a factor of 120 while the Km was unaffected, which emphasizes 
the importance of E24 in both substrate binding and catalysis (Table 3.2). The NatA-
Naa10p-Y26A mutant resulted in a 144-fold decrease in catalytic efficiency, while the 
catalytic efficiency for the NatA-Naa10p-Y139A mutant could not be calculated due to 
the immeasurably high Km (Table 3.2), which is likely caused by the fact that Y139 is 
involved in both a backbone interaction and the Ser1 side chain-binding pocket.  To 
evaluate the active site of the uncomplexed Naa10p, we docked the bisubstrate inhibitor 
into the monomeric structure that is inactive towards the amino-terminal Ser- substrate.  
Consistent with the particular importance of Naa10p residues L22, E24, Y26 and Y139 in 
NatA catalysis of traditional substrates, each of these residues are not in a position for 
productive substrate binding and catalysis in uncomplexed Naa10p, with the exception of 
Y139 (Figure 3.9C).   
Although all of the important catalytic residues noted above for NatA catalysis of 
the Ser-amino terminal substrate appear out of place for catalysis by the Naa10p 
monomer, it is able to catalyze acetylation of the Glu-amino-terminal substrate, 
suggesting that the acetylation reaction by Naa10p is catalyzed through an alternate 
mechanism relative to that of the NatA complex.  To investigate the possibility that the 
Glu-amino-terminal substrate substrate does not require the E24 catalytic residue for 
acetylation, we performed an assay using this substrate and the NatA-E24A mutant.  This 
mutant, which we found will not acetylate the amino-terminal Ser- or Met- amino-
terminal substrates used in this study, is able to acetylate the Glu- amino-terminal 
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substrate with a rate that is only 4.5-fold slower than the rate of the wild type NatA 
complex with its cognate Ser-amino terminal substrate peptide (Table 3.2).  We suspect 
that the more open amino-terminal residue-binding pocket is able to accommodate an 
amino-terminal Glu- substrate peptide and that the carboxylic acid group of the Glu1 side 
chain occupies a position that is very similar to the corresponding group in the wild type 
NatA-E24 side chain; consequently, it seems to be able to play an equivalent role in 
catalysis.  The recovery of activity observed when using this substrate-mutant 
combination further supports the importance of the E24 carboxylic acid moiety in the 
NatA catalytic mechanism. 
To determine the molecular basis for the inability of NatA to acetylate N-terminal 
methionine and glutamate residues, we modeled an amino-terminal glutamate residue and 
docked the human NAA50 substrate into the active Naa10p site (Figure 3.9D).  This 
superposition revealed that Naa10p-E24 would clash with the substrate peptide 
methionine residue, suggesting that Naa10p-E24 is particularly important for excluding 
N-terminal methionine substrates.  This is consistent with the importance of the 
corresponding human Naa50-V29 residue for N-terminal methionine recognition and 
acetylation (Liszczak et al., 2011).  We also modeled substrate amino-terminal Thr- and 
Val- residues, the most bulky NatA substrates, into the active site to show that these side 
chains can also be accommodated without steric clash in the wild type NatA substrate-
binding pocket (Figure 3.9D). 
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Figure 3.8  Inhibitor structures and IC50 curves.  (A) A ChemDraw representation of 
CoA is shown along with R-groups that correspond to the structure of AcCoA, acetonyl 
CoA and the bisubstrate inhibitor (SASEA-CoA). (B) The dose response curves 
corresponding to the titration of SASEA-CoA and acetonyl CoA into a wild type 
Naa10pNaa15p acetyltransferase reaction and a wild type hNaa50p acetyltransferase 
reaction.  IC50 values for each inhibitor are also shown. 
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Figure 3.9  Structure of the NatA complex bound to a bisubstrate inhibitor. (caption 
on following page) 
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Figure 3.9 (continued) (A) The structure of the bisubstrate inhibitor (orange) as it 
appears when bound to Naa10p in the context of the NatA complex.  A simulated 
annealing omit map contoured to 1.5σ is shown in blue. Peptide residues are numbered 
relative to their position in the sequence. (B) A zoom view of the active site of the 
Naa10p enzyme bound to the inhibitor.  Residues that interact with the substrate peptide 
regions are shown in stick format and hydrogen bonds are shown as black dotted lines. 
(C) A model of the inhibitor docked into the inactive form of Naa10p.  Corresponding 
residues of the inactive Naa10p structure that mediate substrate interactions in the active 
Naa10p form of the enzyme are shown in stick format.  (D) A model of the human 
Naa50p substrate and CoA (yellow stick format) docked into the active site of the 
complexed Naa10p.  Glutamate (silver), valine (green) and threonine (blue) substrate 
amino-terminal side chains have been docked into the peptide-binding pocket.  Residues 
from each enzyme that have been shown to interact with their corresponding substrate 
peptides are shown in stick format. 
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Figure 3.10  Catalytic characterization of key NatA mutants.  A bar graph showing 
the catalytic efficiencies of key point mutants.  
N/A = This mutant has a Km greater than 2,000 μM and catalytic efficiency cannot be 
calculated.  
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3.2.4  Catalysis by NatA 
Previous structural and kinetic studies on human NAA50 support a dual base 
mechanism in which NAA50-Y73 and -H112, located in the central core region and C-
terminal segment of the catalytic domain, contribute to proton abstraction from the 
substrate α–amino group to facilitate the acetylation reaction (Liszczak et al., 2011).  An 
active site alignment of these enzymes shows that Naa10p also has two potential general 
bases in corresponding positions, Naa10p-H72 and -H111 (Figure 3.11A).  However, 
point mutations of H72A (kcat = 2.4±0.3 sec
-1
) and H111A (kcat = 2.0±0.2 sec
-1
) each had 
a negligible effect on the rate of catalysis, arguing against the importance of these 
residues in catalysis by Naa10p (Table 3.2).  Notably, NAA50 also has a water molecule 
in the active site that is likely to play a catalytic role, which is not observed in the Naa10p 
active site and further supports the idea that NatA employs a different catalytic 
mechanism (Liszczak et al., 2011). 
The NatA structures reveal that E24, located in the loop between the α1 and α2 
helices in the N-terminal segment of the Naa10p catalytic domain, is in close proximity 
to the amino-terminal residue and could be playing a role in catalysis (Figure 3.11A).  
This is consistent with our observation that the E24Q mutant shows a 120-fold reduction 
in kcat and has a negligible effect on Km , which suggests that the carboxylic acid moiety 
is essential for catalysis, but not required for substrate binding (Table 3.2).  In both Gcn5 
and ESA1, mutating the general base glutamate to a glutamine also results in a decrease 
in kcat by ~2 orders of magnitude, which supports the possibility that Naa10p-E24 of 
NatA could be acting as a general base in the NatA acetylation reaction(Berndsen et al., 
2007; Tanner et al., 1999), whereby the buried glutamate residue harbors an increase in 
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side chain pKa that allows it to directly deprotonate the substrate amino group.  
Alternatively, the glutamate residue could act through an electrostatic mechanism causing 
an induced-dipole on the α-amino group that would increase the nucleophilicity of the 
substrate.  While NatA-Naa10p-E24 functions as an essential catalytic residue, it is also 
possible that NatA-Naa10p-Y139, located in the C-terminal segment of the Naa10p 
catalytic domain, also contributes to catalysis due to its location in the active site and the 
dramatic effect on catalysis observed for the NatA-Naa10p-Y139A mutant. Significantly, 
NatA-Naa10p-R113, also in this C-terminal segment, forms an ionic interaction with 
E24.  An observed 18-fold reduction in catalytic efficiency for the Naa10p-R113A 
mutant suggests that this residue may also be important for proper positioning of the 
Naa10p-E24, altering the pKa of the E24 side chain, or it may have some other function 
in the NatA catalytic mechanism or substrate binding/positioning.  A comparison of the 
catalytic efficiencies of potential key catalytic residues is shown in Figure 3.10.  A 
sequence alignment of the Naa10p catalytic subunits from a diverse group of eukaryotic 
species reveals that all of the α1-α2 loop residues, as well as R113 and Y139, are strictly 
conserved, which reinforces the importance of these residues in catalysis (Figure 3.11B).   
To further dissect the reaction mechanism, we also calculated Ki values of the 
CoA-SASEA inhibitor as well as its mode of inhibition towards both AcCoA and the 
substrate peptide.  Our results (Figure 3.12A-D) reveal that the CoA-SASEA is a 
competitive inhibitor versus AcCoA (Ki=1.1±0.1 μM) and a noncompetitive inhibitor 
versus the substrate peptide (Ki=8.9±0.1 μM).  This pattern of inhibition supports an 
ordered BiBi model for catalysis, with AcCoA binding occurring before the substrate 
peptide (Copeland, 2005).  This type of mechanism was also recently reported for 
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NAA50 in a study that used NMR experiments to show that AcCoA binding induces 
rearrangements in the peptide-binding pocket and that the peptide shows a far greater 
affinity toward the NAA50•AcCoA complex over the apo enzyme. 
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Figure 3.11  The active site of the NatA complex and other GNAT 
acetyltransferases.  (caption on following page) 
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Figure 3.11 (continued)  (A) The active site of the inhibitor-bound Naa10p subunit.  The 
inhibitor (orange) and residues found to be important for catalysis (teal) are shown in 
stick format.  The general bases of the hNAA50 enzyme (pink) and corresponding 
residues in Naa10p are also shown in stick format. (B) Sequence alignment of key 
features from Naa10 catalytic subunits from Schizosaccharomyces pombe (Sp), 
Arabidopsis thaliana (At), Caenorhabditis elegans (Ce), Candida albicans (Ca), 
Drosophila melanogaster (Dm), and Homo sapiens (Hs).  Black circles () have been 
placed above proposed key catalytic residues and crosses (+) have been placed above 
proposed substrate binding residues.  (C) Alignment of the NatA active site with the 
corresponding active sites of other protein and small molecule GNAT enzymes.  Key 
catalytic residues for each enzyme are highlighted.  (D) Sequence alignment of catalytic 
subunits of NAT complexes from .  Black circles () have been placed above proposed 
key catalytic residues and crosses (+) have been placed above proposed substrate binding 
residues Schizosaccharomyces pombe (Sp) and Homo sapiens (Hs). 
   86 
 
Figure 3.12  Bisubstrate inhibition studies.  (A)  Michaelis-Menton plots for Naa10p in 
the presence  of various concentrations of AcCoA (0-500 μM)  with inhibitor 
concentrations ranging from 0-15 µM.  Best fit data corresponds to a competitive mode 
of inhibition (Ki = 1.1±0.1 μM).  (B)  Michaelis-Menton plots in the in presence of 
various concentrations of substrate peptide (0-1000 μM) with inhibitor concentrations 
ranging from 0-30 µM.  Best fit data corresponds to a noncompetitive mode of inhibition 
(Ki = 8.9±0.2 μM).  (C) A Lineweaver-Burke plot corresponding to data shown in (A).  
(D)  A Lineweaver-Burke plot corresponding to data shown in (B).  Detailed 
experimental procedures can be found in ‘Materials and methods’. 
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3.3  Discussion 
 The data presented here reveals that Naa15p allosterically reconfigures the 
Naa10p active site for sequence-specific amino-terminal acetylation. Specifically, this 
study highlights a unique mechanism in which NatA substrate binding specificity is 
coupled to the catalytic strategy that is employed.  This finding is supported by evidence 
that an amino-terminal residue of an incompatible substrate, such as a methionine, would 
have to displace E24, an essential catalytic residue, for binding to occur (Figure 3.9D).  
Furthermore, upon modeling all bulky, β-branched NatA cognate substrate amino-
terminal residues into the binding pocket, we find that none of them clash with the E24 
residue, which further supports the importance of this residue and its role in substrate-
specific acetylation  (Figure 3.9D).   We also note that in the absence of E24, the only 
peptide we found that can still undergo acetylation is the Glu-amino-terminal substrate, 
likely due to the fact that the side chain carboxylic acid moiety is able to functionally 
replace the corresponding group on the E24 side chain. This could also explain the 
activity observed for the Naa10p monomer in the presence of this substrate (Van Damme 
et al., 2011a).  
Comparison of the Naa10p active site with the corresponding region of NAA50 
and other HATs shows significant differences that appear to underlie the fact that Naa15p 
binding is required for Naa10p acetyltransferase activity towards conventional substrates.  
In particular, three catalytically essential Naa10p residues that are located in the α1-α2 
loop that is N-terminal to the catalytic core region, L22, E24, and Y26, are not correctly 
positioned for catalysis in the uncomplexed form of the enzyme (Figure 3.9C).  
Significantly, in the context of the NatA complex, the L22 and Y26 side chains shift from 
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surface exposed positions into the active site while the E24 side chain is repositioned by 
~5 Å to facilitate the observed coupling of substrate binding specificity and catalysis.  
These changes in the Naa10p conformation are essential for productive catalysis of 
traditional substrates.  In contrast, the independently active NAA50 and other HATs have 
their key catalytic residues located on the opposite side of the substrate, either within the 
central core region or the segment C-terminal to the catalytic core region (Figure 3.11C).  
It appears that Naa10p contains its key residues for catalysis on the opposite side of the 
substrate relative to NAA50 and the other HATs to allow for catalytic regulation through 
Naa15p binding.    
A sequence alignment of the Naa10p catalytic subunits from a diverse group of 
eukaryotic species reveals that all of the α1-α2 loop residues, as well as R113 and Y139, 
are strictly conserved, which reinforces the importance of these residues in catalysis 
(Figure 3.11B).  In addition, based on our findings of Naa15p regulation of Naa10p 
activity, we propose that the catalytic subunits of the NatB and NatC NAT complexes are 
modulated for acetylation in similar ways by their auxiliary subunits.  This hypothesis is 
consistent with the strict conservation of the Naa10p-L22, -E24, and Y26 residues across 
catalytic subunits of each of these NAT complexes (Figure 3.11D), which also reinforces 
the importance of this loop for enzymatic activity of NAT enzymes. However, NatB and 
NatC both acetylate methionine containing amino-terminal substrates, so these complexes 
likely use other novel strategies to accommodate their respective substrates.  Many 
protein lysine side-chain acetyltransferases, including HAT1 (Parthun et al., 1996), 
HBO1 (Iizuka and Stillman, 1999) and Sas2 (Sutton et al., 2003), also require auxiliary 
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subunits for activated acetylation and it is of significant interest to determine if they also 
share similar strategies for catalytic regulation with heterodimeric NAT proteins.  
The unique features of the NatA complex could be exploited for the development 
of NatA-specific inhibitors.  Indeed, to our knowledge, the CoA-SASEA NatA inhibitor 
that we have prepared is the most potent NAT inhibitor that has been reported to date. 
This inhibitor may serve as a suitable probe for NatA inhibition in vitro, and although 
peptide-based inhibitors are generally not suitable inhibitors for cell-based studies due to 
their poor ability to penetrate cell membranes, the CoA-SASEA inhibitor may 
nonetheless serve as a starting point for the development of small molecule mimics with 
better pharmacological properties.  Furthermore, our inhibition studies suggest that 
inhibitors targeting the peptide-binding pocket have the potential to specifically inhibit 
NatA relative to other NATs while AcCoA analogues will likely exhibit more 
promiscuous inhibition patterns.  Given the observations that NatA subunits are often 
overexpressed in several different cancer tissues, suggests that NatA inhibitors may have 
therapeutic application (Fluge et al., 2002; Kalvik and Arnesen, 2013; Lim et al., 2006; 
Ren et al., 2008; Yu et al., 2009b).  
 
3.4  Materials and methods  
3.4.1  Naa10p expression and purification 
The full length Naa10p gene (encoding residues 1-177) was cloned out of the 
Schizosaccharomyces pombe genome (ATCC) and several C-terminal truncation 
constructs were engineered into a modified pETDUET vector containing a TEV protease-
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cleavable 6XHis-tag.  All constructs were transformed into Rosetta (DE3)pLysS 
competent E. coli cells, grown to an OD600=0.7 and induced with 0.5 mM IPTG at 16°C 
for ~16 hours.  Cells were isolated by centrifugation and lysed by sonication in a buffer 
containing 25 mM Tris (pH 8.0), 500 mM NaCl, 10 mM β-ME and a complete, EDTA 
free protease inhibitor tablet (Roche).  The solution was isolated and passed over Ni-resin 
(Thermo Scientific), which was subsequently washed with > 20 column volumes of lysis 
buffer supplemented with 25 mM imidazole.  The protein was eluted in the same buffer 
with an imidazole gradient (25-500 mM imidazole) and TEV protease was added to 
fractions containing the target protein for the duration of a 14-hour dialysis into lysis 
buffer.  The solution was passed through an additional nickel column to remove TEV 
protease as well as any uncut Naa10p.  The resin was then washed with ~ 7 column 
volumes of lysis buffer supplemented with 25 mM imidazole, which was pooled with the 
initial flow through.  This solution was dialyzed into a buffer containing 25mM sodium 
citrate monobasic (pH 5.5), 100 mM NaCl and 2 mM DTT and loaded onto a 5 mL 
HiTrap SP ion exchange column (GE Healthcare).  The protein was eluted in the same 
buffer using a salt gradient (100-750 mM NaCl).  Peak fractions were concentrated to 8.0 
mg/mL (10kDa concentrator; Amicon Ultra, Millipore) as measured by UV280 absorbance 
(extinction coefficient = 18,000), for crystallization trials.  The selenomethionine 
derivative was prepared by expressing Naa10p (residues 1-156) in minimal medium 
(Molecular Dimensions) containing 50 μg/L of selenomethionine (Sigma), which was 
purified using the scheme described above. 
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3.4.2  Naa10pNaa15p complex expression and purification  
The full length Naa15p gene (encoding residues 1-729) was cloned out of the 
Schizosaccharomyces pombe genome and engineered into MCSI of a modified 
pETDUET vector containing a TEV protease-cleavable 6XHis-tag.  DNA encoding 
residues 1-156 of Naa10p was engineered into MCSII of the corresponding vector.  Cells 
were grown and the binary protein complex was prepared essentially as described for 
Naa10p, except that the first of two peaks that eluted from the HiTrap SP ion exchange 
column was concentrated to 1mL, and loaded onto an s200prep gel filtration column (GE 
Healthcare) in a buffer containing 25 mM HEPES (pH 7.0), 200 mM NaCl and 1 mM 
TCEP.  This protein was concentrated to 15 mg/mL as measured by UV280 (extinction 
coefficient = 100,000) for crystallization trials.  The selenomethionine labeled complex 
was obtained in as described above.  Point-mutation proteins were generated using the 
Stratagene QuikChange protocol and protein harboring point mutations was expressed 
and purified using the protocols described above (Braman et al., 1996). 
 
3.4.3  Naa10p crystallization and structure determination   
Naa10p at a concentration of 8 mg/mL was mixed with AcCoA at a 1:3 molar 
ratio.  Initial crystallization hits were obtained from an Naa10p construct containing 
residues 1-161 (Naa10p (1-161)) using hanging drop vapor diffusion at 20°C with a well 
solution containing 16% PEG 8000 (Hampton Research), 10% ethylene glycol and 0.1M 
HEPES (pH 7.5) and yielded poor diffraction.  These crystals were used to seed entire 
grid screens with Naa10p(1-156), which did not crystallize in the absence of the seed 
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crystals.  Large crystals of Naa10p(1-156) were obtained from this screen in a 1:1 
mixture of protein and well solution (14% PEG 3350 and 0.1M bis-tris (pH 6.5)) using 
hanging drop vapor diffusion at 20°C.  An additive screen (Hampton Research) revealed 
that these crystals could be reproduced in the absence of seed crystals when 10% glycerol 
was present as an additive in the crystallization drop.  Final crystallization conditions of 
the Naa10p protein (construct 1-156) were optimized and include a drop with a 
2.5:0.5:2.0 ratio of protein (8 mg/mL): glycerol (50%): well solution, mixed in that order.  
Selenomethionine crystals of this construct were obtained using identical conditions with 
a lower protein concentration (6.5 mg/mL).  Diffraction quality crystals required 1-3 days 
to grow to maximum dimensions.   
Datasets were collected at beamline X29A at the National Synchrotron Light 
Source (Brookhaven National Laboratory) processed using HKL2000 (Otwinowski and 
Minor, 1997).  Initial molecular replacement trials with the program Phaser were 
performed using several truncated variants of the hNaa50p structure (PDB ID:  3TFY) as 
a model, but were unable to provide electron density maps suitable for model building 
(McCoy et al., 2007).  A dataset was then collected on the selenomethionine-labeled 
protein at the selenium peak wavelength (0.9795Å) but selenium sites could not be 
identified using single wavelength anomalous diffraction (SAD) or single isomorphous 
replacement with anomalous scattering (SIRAS).  The selenium sites were located by 
performing molecular replacement (as described above) on the selenomethionine 
derivative dataset, contouring the output electron density map to 3.0σ, and placing 
selenium atoms at the resulting peaks in Coot (Emsley and Cowtan, 2004).  These sites 
were input into Phaser along with the hNaa50p model, and an MR-SAD approach yielded 
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high quality electron density maps.  Initial model building was carried out using 
ARP/wARP and refinement was carried out using Phenix.refine (experimental phases 
excluded throughout refinement) while applying 2-fold NCS (Adams et al., 2010; Langer 
et al., 2008).  TLS was used in later stages of refinement (TLS groups defined using the 
open access server) (Painter and Merritt, 2005, 2006).  Manual refinement and additional 
model building were performed using the program Coot.  The selenomethionine 
containing crystals diffracted to a higher resolution (2.00 Å) than the wild type crystals 
(2.60 Å) and so the structure used in all analyses was that of the SeMet-derivatized 
protein.  The final model was checked for errors using a composite omit map generated 
by AutoBuild in the Phenix suite of programs (Adams et al., 2010). 
 
3.4.4  Naa10pNaa15p crystallization and structure determination  
The Naa10p (1-156)Naa15p (full length) complex was concentrated to 12 
mg/mL and mixed with 3X cofactor (AcCoA or bisubstrate inhibitor) and allowed to 
stand for 12-15 hours at 4°C.  The initial crystallization hit was obtained using hanging 
drop vapor diffusion at 20°C in a well solution containing 10% PEG 4000, 10% 
isopropanol and 0.1M HEPES (pH 7.0) (all reagents from Qiagen).  The best crystals 
were obtained by mixing protein:well at a 2.0μL:2.0μL ratio and grew to maximum 
dimensions in 7-10 days.  These crystals were transferred into mother liquor 
supplemented with ethylene glycol in 5% increments (15%, 20%, 25%) for 1 minute at 
each concentration and finally flash-frozen in liquid nitrogen.  The selenomethionine-
labeled protein required that the protein buffer be supplemented with 1mM reduced L-
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Glutathione and 1mM oxidized L-Glutathione for crystallization to occur in conditions 
identical to those described for the native Naa10pNaa15p complex. The crystals were 
cryoprotected in the stepwise manner described above.  To derivatize native crystals with 
Pt (II), the crystals were transferred into mother liquor supplemented with 1mM K2PtBr4 
for 20 minutes before cryoprotection using the method described for the native 
Naa10pNaa15p complex.   
Datasets were collected at beamlines X25 and X29A at the National Synchrotron 
Light Source (Brookhaven National Laboratory) and processed using HKL2000. For 
phasing, a total of 1,000 degrees (1°/frame) were collected on a single derivatized crystal 
(500 frames at the peak wavelength, and 500 frames at the inflection wavelength) to 
reach desirable completeness and redundancy in the P1 space group, and datasets were 
processed to 3.50 Å resolution.  The two wavelength MAD data was used by the Hybrid 
Substructure Search in Phenix to identify a total of 8 heavy atom sites in the asymmetric 
unit and initial phases were obtained using SOLVE (Adams et al., 2010; Terwilliger and 
Berendzen, 1999).  Density modification was performed in Resolve by applying 4-fold 
NCS (corresponding to each heterodimer) and using histogram matching and solvent 
flattening (Terwilliger, 2000).  Initially, the Naa15p helices were built as polyalanine 
chains and the Naa10p molecules were manually placed into the density-modified map 
using the program Coot.  The resulting structure was used as a molecular replacement 
model for the selenomethionine derivative dataset that was collected at the selenium peak 
wavelength and processed to 3.35 Å resolution.  A total of 80 selenium sites were located 
manually in the asymmetric unit by contouring the map to 3.0σ and placing selenium 
atoms in the peaks in Coot.  These sites were used to place methionine residues in 
   95 
Naa15p, and manual model building was completed in coot using the methionine residues 
as a guide.  The final structure was used as a molecular replacement model for the high-
resolution datasets (500° of data each) of the Naa10pNaa15pAcCoA (3.10 Å 
resolution) and the Naa10pNaa15pbisubstrate inhibitor (2.60 Å resolution) complexes.  
Refinement of the binary complex structures was carried out in Phenix and 4-fold NCS 
restraints were applied to two separate groups, the full-length Naa10p molecules, and 
residues 100-731 of Naa15p.  The positioning of the first 5 N-terminal helices in the 
Naa15p subunit is slightly different in each heterodimer, so NCS could not be applied to 
this region.  TLS was also used in later stages of refinement (TLS groups defined using 
the open access server).  The backbone for the α20-α21 loop from residues 356-377 can 
be traced, however it is largely disordered (average B-factor=196 Å
2
) as it likely samples 
numerous conformations in the crystal.  No density was observed for a loop from 
residues 633-641 and so this region was omitted from the final structure.  Naa15p 
molecules were built starting between residues 1 and 5 depending on the chain and 
dataset.  The final models were checked for errors using a simulated annealing composite 
omit map generated by AutoBuild in the Phenix suite of programs.   
All surface area and distance calculations, as well as three-dimensional alignment 
RMSDs and graphics were generated in PyMol (Delano Scientific LLC).   
 
3.4.5  Acetyltransferase Assays 
Naa10p•Naa15p acetyltransferase assays were carried out with 100 nM complex 
at 25°C for 3-120 min. (3 min for wild type protein and longer for mutant complexes that 
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were catalytically deficient) in 100mM Tris (pH 8.0) and 50 mM NaCl unless stated 
otherwise. A saturating amount of AcCoA (500 μM) was used in all enzymatic reactions, 
and the substrate peptide (NH2-SASEAGVRWGRPVGRRRRP-COOH; GenScript) 
concentration was varied to determine steady-state catalytic parameters. The first seven 
residues of this peptide correspond to the amino-terminal sequence of a protein that has 
been shown to be highly amino-terminally acetylated in yeast while the C-terminal 12 
residues form a basic tag that make the substrate compatible with our assay(Arnesen et 
al., 2009).  The Glu- amino-terminal substrate peptide (NH2- 
EEEIAALRWGRPVGRRRRP-COOH; Genscript) was designed with the same rationale, 
except that the first seven residues are from the Naa10p in vivo substrate, γ-actin. The 
Met- amino-terminal substrate peptide (NH2- MLGPEGGRWGRPVGRRRRP-COOH; 
Genscript) also follows the design rationale described above, with the first seven residues 
corresponding to the in vivo substrate, hnRNP F.  In the assay, radiolabeled [
14
C]acetyl-
CoA (4 mCi/mmol; PerkinElmer Life Sciences) was mixed with the substrate peptide and 
allowed to incubate with enzyme in a 25 μL reaction volume at 25°C. To quench the 
reaction, 20 μL of the reaction mixture was added to P81 paper discs (Whatman), and the 
paper discs were immediately placed in wash buffer. Washes were then carried out three 
times in 10 mM HEPES (pH 7.5), with each wash lasting 5 min, to remove unreacted 
AcCoA. The papers were then dried with acetone and added to 4 ml of scintillation fluid, 
and the signal was measured using a Packard Tri-Carb 1500 liquid scintillation analyzer. 
Background control reactions were performed in the absence of enzyme. Reactions were 
also performed in the absence of the substrate peptide to ensure that any possible signal 
due to autoacetylation was negligible.  
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For the uncomplexed Naa10p subunit, reactions with the Ser- amino-terminal 
peptide were carried out for 1 hour using 500 μM AcCoA, substrate peptide (100-1,500 
μM) and up to 1 μM untagged enzyme.  No activity could be detected.  Reactions with 
the Glu- amino-terminal peptide were performed at 25°C for 30 minutes in the presence 
of 200 nM enzyme and 500 μM AcCoA at various peptide concentrations (50-1000 μM).  
For the NatA complex, substrate peptide Km and Vmax parameters were derived by 
titrating the substrate peptide at eight different concentrations ranging from 100 to 1500 
μm in the presence of 500 μM AcCoA.   To obtain kinetic data for the point mutants 
L22A, Y26A, and Y139A, 500 nM of enzyme was used in the reaction.  Additionally, the 
AcCoA Km values for the wild type protein as well as the L22A mutant were determined 
by titrating the AcCoA at 8 different concentrations (ranging from 20-300 μM) in the 
presence of 1.5 mM substrate peptide.  All reactions were performed in triplicate. All 
radioactive count values were converted to molar units using a standard curve created 
with known concentrations of radioactive acetyl-CoA added to scintillation fluid.  The 
program GraphPad Prism version 5.01 was used for all data fitting to the Michaelis-
Menten equation (Fersht, 1998). 
Inhibition assays were carried out in a similar manner as described above.  These 
reactions were performed using 100nM wild type protein for 3 minutes in the buffer 
described for the previous assays.  IC50 values for Naa10p were calculated by titrating 
inhibitor (CoA-SASEA:  0.01-120 μM and acetonyl CoA:  5-10,000 μM) into reaction 
mixtures containing fixed concentrations of substrate peptide (500μM) and AcCoA (200 
μM).  Similarly, IC50 values for NAA50 (expressed and purified as previously 
described(Liszczak et al., 2011)) were calculated by titrating inhibitor (CoA-SASEA:  
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0.01-240 μM and acetonyl CoA:  5-10,000 μM) into reaction mixtures containing fixed 
concentrations of substrate peptide (1200 μM) and AcCoA (200 μM).  To clarify, peptide 
concentrations were held constant at Km.  To calculate the Ki of the CoA-SASEA 
inhibitor versus AcCoA, substrate peptide concentration was held constant at 1200 μM 
and kinetic curves were generated using AcCoA concentrations ranging from 15-500 μM 
in the presence of inhibitor concentrations ranging from 0-15 μM.  To calculate the Ki of 
the CoA-SASEA inhibitor versus substrate peptide, AcCoA concentration was held 
constant at 500 μM and kinetic curves were generated using peptide concentrations 
ranging from 200-1000 μM in the presence of inhibitor concentrations ranging from 0-30 
μM.  All reactions described here were performed in duplicate and data were fit to a 
sigmoidal dose-response curve using GraphPad Prism version 5.01. 
 
3.4.6  Bisubstrate inhibitor synthesis 
The peptide SASEA was synthesized on a 100 μmol scale using standard Fmoc 
solid-phase synthesis techniques.  Rink amide resin (100-200 mesh), Fmoc-Ala-OH, 
Fmoc-Glu(tBu)-OH, Fmoc-Ser(tBu)-OH, and 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU) were purchased from Novabiochem 
(currently EMD Millipore; Billerica, MA).  All other reagents, including Sigmacote ®, 
were purchased from Sigma-Aldrich (St. Louis, MO).  A clean, oven-dried glass reaction 
vessel (RV) was treated with Sigmacote and rinsed with dimethylformamide (DMF) prior 
to use.  Rink amide resin (151 mg; substitution 0.66 mmol/g) was transferred to the RV 
and stirred with 6 mL DMF twice for 15 min.  After each incubation, DMF was removed 
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with vacuum suction.  The beads were incubated with 20 % piperidine in DMF (5 mL) 
for 20 min with magnetic stirring to remove the Fmoc protecting group from the resin. 
The spent solution was removed with vacuum suction and the beads were rinsed 
thoroughly with DMF.  Excess DMF was removed with vacuum suction and the beads 
were stirred with a solution of Fmoc-Ala-OH and HBTU in DMF (5 equiv; 83 mM, 6 
mL) and diisopropylethylamine (10 equiv; 175 μL).  After 30 min, the spent solution was 
drained from the RV and the beads were washed extensively with DMF.  Excess DMF 
was removed with vacuum suction.  Subsequent amino acids were added iteratively using 
analogous Fmoc-deprotection and coupling procedures.  After removal of the final N-
terminal Fmoc-protecting group, bromoacetic acid was coupled to the peptide as an 
active O-acylisourea using carbodiimide chemistry.  Bromoacetic acid (10 equiv; 139 
mg, 1 mmol) was pre-activated with N,N'-diisopropylcarbodiimide (20 equiv; 309 μL, 2 
mmol) in 2 mL dry CH2Cl2 for 20 min with stirring.  The solvent was then removed 
under reduced pressure and the residue was transferred to the RV as a solution in 6 mL 
DMF.  The resulting slurry was allowed to react for 1 h with constant stirring.   The resin 
beads were then thoroughly washed with DMF and CH2Cl2.  Residual solvent was 
removed with vacuum suction and the beads were dried under vacuum for 30 min.  A 
cocktail of trifluoroacetic acid (TFA)/triisopropylsilane/water (38:1:1 v/v) was used for 
global deprotection and resin cleavage.  The resin beads were incubated with fresh 6 mL 
portions of this solution for 60 min and then 30 min on a rotisserie. The cleavage solution 
was drained from the RV under N2 flow after each incubation.  The solutions were 
combined and concentrated under reduced pressure.  The residue was dissolved in a 
H2O/CH3CN solution (3:1 v/v) and lyophilized.  The crude, lyophilized powder was 
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dissolved in 3 mL triethylammonium bicarbonate buffer, pH 8.00.  A 1 mL portion of this 
solution was mixed with coenzyme A hydrate (25 mg, 33 μmol) and the resulting 
solution was allowed to react for 4 h at room temperature and then overnight at 4 °C.  
The peptide conjugate was purified by reversed-phase high-performance liquid 
chromatography (HPLC) using a Varian ProStar HPLC instrument outfitted with a diode 
array detector (currently Agilent Technologies; Santa Clara, CA) and Vydac 218TP C18 
analytical and prep columns (Grace/Vydac; Deerfield, IL) with a linear solvent gradient.  
The aqueous phase was 0.1 % TFA in H2O and the organic phase was 0.1 % TFA in 
CH3CN.  The gradient remained isocratic at 98 % aqueous phase for 5 min, before 
ramping to 81 % aqueous phase over 16 min, then to 0% aqueous phase over 6 min, then 
returning to 98% aqueous phase during a 9 min wash out period.  The peptide conjugate 
eluted around 15 min with this method.  An analytical trace of the purified compound is 
shown in Figure 3.13.  Purified material was lyophilized.  Matrix-assisted laser 
desorption ionization (MALDI) mass spectra were collected with a Bruker Microflex 
LRF MALDI-TOF mass spectrometer to confirm identity.  MALDI-MS(-) m/z clacd for 
C40H65N13O26P3S
-
 [M-H]
-
 1268.31, found 1268.32. 
 
3.4.7  Materials and methods (‘Future directions’) 
 Isolation of ribosomes was carried out as previously described (Ben-Shem et al., 
2011; Ben-Shem et al., 2010).  Purified ribosomes were resuspended in a buffer 
containing 10 mM HEPES (pH 7.5), 50 mM KOAc, 10 mM NH4Cl, 5 mM Mg(OAc)2, 5 
mM BME and NatA was dialyzed into an identical buffer and immobilized on the nickel 
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column.  Ribosomes were passed over the column 5 times and the resin was subsequently 
washed with 10 CV of lysis buffer supplemented with 25 mM imidazole.  The 
NatAribosome complex was eluted from the column using lysis buffer supplemented 
with 300 mM imidazole.  The elution was sent directly to collaborators for EM studies.  
Control experiments were performed to show that ribosome does not interact with nickel 
resin in the absence of the NatA complex. 
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Figure 3.13  Analytical HPLC trace of purified SASEA-CoA.  Absorbance at 260nm 
has been normalized.  The solvent gradient has been provided in the supplemental text.
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3.5  Future directions and NatAribosome complex studies 
There are many outstanding questions in the NAT field regarding the 
NatAribosome interaction.  In vivo NatAribosome pull-downs provide evidence that 
ribosomal proteins Rpl25p and Rpl35p in Saccharomyces cerevisiae, which are in close 
proximity to the ribosomal exit tunnel, are responsible for the NatA interaction (Polevoda 
et al., 2008).   However, it is unclear whether all NAT complexes alternate with one 
another for this binding site during this translation or if the NATs are able to associate 
with the ribosome simultaneously.  It is also possible that different ribosomes selectively 
interact with different NAT complexes and that there is no competition between NATs 
for interaction with the ribosome.  This scenario would require a mechanism of ribosomal 
mRNA selectivity to ensure that each translated protein meets the substrate requirements 
for the corresponding NAT. 
To explore these possibilities, we isolated ribosomes from Schizosaccaromyces 
pombe and formed a ribosomeNatA complex for electron microscopy (EM) studies. We 
used nickel affinity pull-downs to verify that His-NatA is able to interact with the 
ribosome in vitro and found that while the interaction does occur, we are unable to isolate 
a 1:1 complex and frequently had to work with a solution containing a large molar excess 
of NatA (Figure 3.14A and B).   There are several factors that may be affecting the 
stoichiometry of our complex.  It is very unlikely that the NatA complex binds to the 
ribosome with high affinity.  There are a plethora of proteins that interact with the 
ribosome near the peptide exit tunnel throughout translation, and it is a distinct possibility 
that they have overlapping binding sites and are only transiently associated.  Furthermore, 
activity of most of these proteins, such as methionine aminopeptidases and NATs, is only 
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observed at certain points during translation (see Chapter 1) and it would not be prudent 
for the ribosome to develop a high affinity for these enzymes.  A non-specific interaction 
region with a low affinity for binding partners would support the dynamic equilibrium of 
ribosomal binding partners that is observed near the peptide exit tunnel during 
translation.  It is also possible that the unbound ribosomes from our pull-down are 
dedicated to interacting with other NATs, or that the NatA binding site is occupied by 
endogenous proteins.  To circumvent these issues, our EM collaborators are attempting to 
pick individual, NatA-bound ribosomes.  Optimization of the purification is also 
underway to try to separate excess NatA from the ribosomeNatA complex.
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Figure 3.14  NatA interacts with the 80S ribosome in vitro.  (A) His-tagged NatA 
mixed with the untagged ribosome and purified using nickel resin. (B)  The pull-down 
experiment shown in (A) in the absence of NatA. 
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Implications for the evolution of eukaryotic amino-terminal acetyltransferase (NAT) 
enzymes from the structure of an archaeal orthologue 
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4.1  Introduction and summary 
 As we have seen in previous chapters, NatA and Naa50p use different catalytic 
strategies to achieve substrate-specific acetylation. In the NatA complex, binding of 
noncognate substrate sequences is possible; however, the enzyme-substrate interaction 
would inactivate the enzyme by displacing an essential general base that is located in the 
substrate amino-terminal residue side chain-binding pocket (P1 pocket).  On the other 
hand, Naa50p excludes binding of NatA substrate peptides through the use of an open, 
hydrophobic P1 pocket that specifically selects for an amino-terminal Met- residue.  As a 
result, residues involved in deprotonation of the Met- substrate peptide are located across 
the active site from this pocket, where NatA has no catalytically essential residues.  In 
addition to characterizing detailed strategies for catalysis, these structures also reveal a 
conserved three-dimensional NAT fold that appears to be required for activity and 
describe how the Naa15p auxiliary subunit is able to stabilize Naa10p in this active 
conformation. 
While only six amino-terminally acetylated proteins have been identified in E. 
coli, large-scale proteomics studies of three different archaeal species revealed that ~14-
29% of all proteins isolated were acetylated at their amino-terminus, suggesting that 
prevalence of amino-terminal acetylation in this domain is somewhere between 
prokaryotes and eukaryotes (Aivaliotis et al., 2007; Falb et al., 2006; Kirkland et al., 
2008; Polevoda and Sherman, 2003b; Soppa, 2010; Waller, 1963).  Analysis of the 
thermophilic archaea Sulfolobus solfataricus genome allowed for identification of a 
protein with 37% sequence identity to human Naa10p, which is believed to be the only 
NAT in this species (Mackay et al., 2007).  In agreement with this hypothesis, the same 
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study showed that this protein is able to independently acetylate NatA substrates as well 
as amino-terminal Met- substrates in vitro (Mackay et al., 2007). Furthermore, no 
auxiliary subunit homologues can be identified in this genome, suggesting that this 
archaeal species dedicates just one protein to a task that requires at least nine unique 
proteins in humans.  This ancestral NAT variant, herein referred to as ssNAT, is an ideal 
candidate for probing the evolution of this family of enzymes and the strategies they 
employ to achieve substrate-specific acetylation. 
In order to gain insight into the evolution of NAT enzymes, we solved the x-ray 
crystal structure of an archaeal NAT from Sulfolobus solfataricus to 1.98 Å resolution. 
Through the use of mutagenesis and kinetic analysis, we show that the active site of this 
enzyme represents a hybrid of the NatA and NatE active sites and we highlight features 
of this protein that allow it to facilitate catalysis through both the NatA and NatE 
catalytic strategies.  Notably, this is the first acetyltransferases to be identified that has 
the ability to facilitate substrate acetylation through two independent catalytic strategies.  
Taken together, the structural and biochemical data presented here has implications for 
the evolution of eukaryotic NAT enzymes and the substrate specificities therein. 
 
4.2  Results 
4.2.1  Overall structure of the active ssNAT enzyme 
Crystals of the ssNAT enzyme (residues 50-216 of 215) bound to AcCoA were 
obtained using recombinant protein expressed in E. coli and diffracted to 1.98 Å 
resolution in the spacegroup C2 with 1 molecule per asymmetric unit cell.  The structure 
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was determined with molecular replacement using ssARD1 (PDB ID: 2X7B) as a search 
model.  Electron density was observed from residues 60-216 and the structure was 
refined to a final Rwork/Rfree of 19.9%/24.3% (Table 4.1).  The ssNAT structure adopts a 
Gcn5-related N-acetyltransferase (GNAT) fold with a central AcCoA binding core region 
and flanking N- and C- terminal segments most similar to the active form of the human 
NatA catalytic subunit Naa10p (RMSD = 1.46 Å) and NatE/Naa50p (RMSD = 1.98 Å)  
(Figures 4.1A and 4.1B).  ssNAT also contains an extended β3-β4 loop that is the only 
nonconserved feature in the catalytic core of this enzyme relative to the eukaryotic NATs 
(Figure 4.1B). Furthermore, an alignment of ssNAT with the uncomplexed, inactive form 
of Naa10p reveals more significant differences, particularly in regard to the position of 
the α1-loop-α2 segment (Figure 4.1C).  More specifically, the C-terminal portion of the 
α1 helix in ssNAT is extended by one complete helical turn, a conformation that Naa10p 
can only adopt in the presence of its auxiliary subunit.  This helix extension, which is also 
present in Naa50p, seems to be crucial for proper positioning of the α1-α2 loop, a region 
that has been shown to be essential for substrate-specific acetylation by both eukaryotic 
NATs discussed here.  Notably, the α1-loop-α2 segments in ssNAT, Naa50p and the 
active form of Naa10p all adopt nearly identical conformations, which is in support of a 
previous report that ssNAT is independently active. 
   110 
Table 4.1  Data collection and refinement statistics for ssNAT. 
 
 
Values in parentheses are for the highest resolution 
shell.  Rfree was calculated using 5% of the 
reflection data chosen randomly and omitted at the 
start of refinement. 
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Figure 4.1  Overall structure of the ssNAT enzyme. (A)  The structure of the ssNAT 
enzyme (tan cartoon representation) bound to AcCoA (gray stick representation).  
Elements of secondary structure have been labeled.  (B) A three-dimensional alignment 
of the ssNATAcCoA complex with NAA50p (red cartoon representation) and the 
complexed, active form of Naa10p (teal cartoon representation).  A color-coded legend is 
also included. (C)  A three-dimensional alignment of the ssNATAcCoA complex with 
the uncomplexed, inactive Naa10p (silver cartoon representation).  Regions of negligible 
structural variation are shown at 50% transparency.  The first two α-helices are labeled. 
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4.2.2  Implications for the evolution of NAT substrate-acetylation specificity  
The structure of the NatA complex bound to a bisubstrate peptide-CoA conjugate 
inhibitor established the position of the substrate amino-terminal residue in the active site 
of the catalytic subunit.  An alignment of the active site from this structure with the 
corresponding region of ssNAT reveals that all key catalytic and cognate substrate 
binding residues in the active site of Naa10p are conserved in ssNAT (Figure 4.2A).  
Specifically, residues L82, E84 and Y86 in the α1-α2 loop of ssNAT align with 
corresponding residues of Naa10p.  Similarly, ssNAT residues R178 and Y203 
correspond to Naa10p residues R113 and Y139. In contrast, another alignment of the 
ssNAT active site with the ternary Naa50p•CoA•substrate peptide fragment structure 
shows significant differences in the amino-terminal residue binding pockets of the two 
enzymes (Figure 4.2B). In Naa50p, residues F27, P28, V29 and I142 align with ssNAT 
residues L82, E84, Y86 and R178, and form a substantially more open, hydrophobic 
pocket that is ideal for the amino-terminal Met- substrate for Naa50p.  Indeed, it appears 
that ssNAT-E84 would clash with the Met- side chain of a Naa50p substrate peptide 
(Figure 4.2C).  Therefore, at first glance, it appears that ssNAT is more tailored for 
binding to NatA vs. NatE substrates.   
In order to directly establish the ability of ssNAT to process NatA and E 
substrates, we generated catalytic parameters for the enzyme against amino-terminal Ser- 
and Met- containing peptides (Tables 4.2 and 4.3).  Consistent with the structural 
comparison, we observed that ssNAT had a preference for the NatA/Naa10p over the 
NatE/Naa50p substrate; specifically, ssNAT had a Km for the Ser- amino-terminal 
Naa10p substrate that is 7.4-fold lower than its Km for the Naa50p Met- amino-terminal 
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substrate and the kcat towards the Ser- amino-terminal substrate is 4.5-fold higher than the 
kcat towards the Met- amino-terminal substrate (Figure 4.3A and B).  While this enzyme 
displays more favorable catalytic parameters with the Ser- substrate, its ability to modify 
amino-terminal Met- substrates is in stark contrast with NatA, which shows only 
background acetylation levels with similar peptides. To directly test the importance of 
ssNAT-E84 in N-terminal residue processing, we prepared ssNAT-E84A/V mutants and 
assayed their ability to process a Met- amino-terminal substrate peptide. As expected, we 
found that these mutants were more accommodating towards the Met substrates, as 
evidenced by increases in the kcat of the enzyme by 4.6-fold and 2.5-fold, respectively, 
towards the Met- amino-terminal substrate while the kcat towards the Ser-amino-terminal 
substrate was unaffected.  These mutants also resulted in an increased Km for the Ser- 
amino-terminal substrate (4.1-fold and 3.5-fold, respectively) with no effect on the Km for 
the Met- amino-terminal substrate.  Furthermore, an alanine point mutation at R178, 
which also contributes to the hydrophilicity of the binding pocket and forms an ionic 
interaction with E84, exhibited a 2.5-fold increase in kcat towards the Met- amino-
terminal substrate with no effect on the kcat towards the Ser-amino-terminal substrate.  
These results strongly support our previous hypothesis that Naa50p, which has a valine 
(V29) in the position of ssNAT-E84, uses a more open hydrophobic binding pocket to 
achieve Met- amino-terminal substrate binding specificity. 
The Y86 and Y203 residues in ssNAT are conserved in both Naa10p and Naa50p, 
and form hydrogen bonds with substrate peptide backbone carbonyl groups in each of the 
previously reported structures (Figure 4.2A and B).  While these residues do form van der 
Waals interactions with the amino-terminal residue of the substrate peptide in each 
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structure, it seems that their primary function is to anchor the substrate peptide to the 
enzyme in a catalytically competent position and it is unlikely that they play a role in 
substrate specificity.  We found that the ssNAT-Y86F and ssNAT-Y203F mutants do not 
affect the Km in the context of the Met- amino-terminal substrate but do show decreases 
of 3.2-fold and 5.2-fold in kcat, respectively.  The same mutations show no effect on 
catalysis or substrate binding relative to wild type enzyme in the context of the Ser- 
amino-terminal substrate.  Thus, the substrate peptide backbone interactions are more 
critical for productive binding of the Met- amino-terminal substrate, likely because the 
ssNAT amino-terminal residue binding pocket favors binding of the Ser- substrate over 
the Met- substrate.   
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Figure 4.2  ssNAT active site and catalytic strategies.  (caption on following page) 
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Figure 4.2 (continued) (A)  A three-dimensional alignment of the ssNAT active site 
(tan) with the corresponding region in Naa10p (teal).  Putative ssNAT substrate binding 
and catalytic residues are shown in stick format as are corresponding residues in Naa10p.  
The bisubstrate inhibitor from Naa10p is shown in silver stick format and residues from 
the peptide portion of this inhibitor are labeled with orange numbers.  Key secondary 
structure elements are also labeled.  Hydrogen bonds are represented as black dotted 
lines.  (B) A three-dimensional alignment of the ssNAT active site (tan) with the 
corresponding region in Naa50p (pink).  Putative ssNAT substrate binding and catalytic 
residues are shown in stick format as are corresponding residues in Naa50p.  The CoA 
and substrate peptide ligands from Naa50p are shown in yellow stick format and residues 
from the substrate peptide are labeled with yellow numbers.  Key secondary structure 
elements are also labeled. Hydrogen bonds are represented as black dotted lines.  (C) 
ssNAT catalytic residues from catalytic strategy 1 are shown in tan stick format and 
aligned with catalytic residues from Naa50p (pink stick format).  A conserved active site 
water molecule is shown as a light blue sphere.  The bisubstrate inhibitor from Naa10p is 
shown in silver stick format and the CoA and substrate peptide ligands from Naa50p are 
shown in yellow stick format.  Residues from the peptide portions of these ligands are 
labeled as orange numbers. (D) ssNAT catalytic residues from catalytic strategy 2 are 
shown in tan stick format and Naa10p residues are shown in teal stick format.  The 
bisubstrate inhibitor from Naa10p is shown in silver stick format and the CoA and 
substrate peptide ligands from Naa50p are shown in yellow stick format.  Residues from 
the peptide portions of these ligands are labeled as orange numbers.  A hydrogen bond is 
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represented as a black dotted line.    A color-coded legend for the panel has been included 
for clarity. 
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Figure 4.3  Catalytic parameters for mutant ssNAT enzymes relative to wild type.  
(caption on following page) 
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Figure 4.3 (continued) (A) kcat values for the wild type (WT) ssNAT and accompanying 
mutants towards both the Ser- amino-terminal substrate peptide (silver bars) and the Met- amino-
terminal substrate peptide (yellow bars).  All values have been normalized to the kcat value 
calculated for the WT enzyme.  (B) Km values for the WT ssNAT and accompanying mutants 
towards both the Ser- amino-terminal substrate peptide and the Met- amino-terminal substrate 
peptide.  All values have been normalized to the Km value caluculated for the WT enzyme.  All 
numbers were calculated by fitting data to the Michaelis-Menten equation.  A complete table of 
kinetic data can be found in SI Materials and Methods. 
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Table 4.2  The kcat values calculated for all ssNAT variants with the Ser- substrate 
peptide and the Met- substrate peptide. 
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Table 4.3  The Km values calculated for all ssNAT variants with the Ser- substrate 
peptide and the Met- substrate peptide. 
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4.2.3 Characterization of two independent catalytic mechanisms strategies by ssNAT  
Naa50p uses a two-base mechanism to carry out substrate α-amino group 
deprotonation and facilitate catalysis.  These two bases, Naa50p-Y73 and Naa50p-H112, 
are on the β3 and β4 strands respectively, and are representative of the traditional general 
base positions in GNAT enzymes (Figure 4.2B) (Marmorstein, 2004; Vetting et al., 
2005).  In Naa10p, the Naa50p-Y73 and Naa50p-H112 residues are replaced by Naa10p-
H72 and Naa10p-H111, respectively, of which Naa10p-H72 is flipped out of the active 
site and not in a position to act as a general base (Figure 4.2A).  It is therefore not 
surprising that neither of these residues is crucial for catalysis by Naa10p.  The 
corresponding active site positions in ssNAT are occupied by ssNAT-H137 and ssNAT-
E176, both of which have side chains directed into the active site that align well with 
Naa50p-Y73 and Naa50p-H112.  To assess the roles of ssNAT-H137 and ssNAT-E176 in 
catalysis, we used site-directed mutagenesis to make single and double mutants at these 
sites and kinetically characterized the mutant enzymes.  The ssNAT-H137A/F/Q 
mutations were found to all inactivate the enzyme toward the Met- substrate while the 
ssNAT-E176Q mutant showed a 5.2-fold reduction in kcat towards this substrate with a 
negligible effect on Km. Although it is possible that ssNAT-H137 is also involved in 
productive substrate binding, the ssNAT enzyme seems to use an Naa50p-like two 
general base strategy (herein referred to as ‘strategy 1’) to deprotonate the α-amino group 
of the Met- amino-terminal substrate (Figure 4.2C).  Remarkably, however, we found that 
the three mutations discussed here all have less than a 2-fold effect on the kcat of the 
enzyme towards the Ser- amino-terminal substrate, and the ssNAT-H137A/E176Q is the 
only mutant that has an effect on Km, which increases by 4.3-fold. This finding suggests 
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that there is an alternate catalytic strategy within the enzyme that is able to facilitate the 
acetylation reaction in the presence of the Ser- amino-terminal substrate.   
Structural and mutational analysis of Naa10p in the context of the NatA complex 
suggests that Naa10p-E24 is an essential general base residue as evidenced by a >100-
fold reduction in catalysis observed for the E24Q mutant, with no effect on Km. 
Additionally, this study revealed that Naa10p-R113 and Naa10p-Y139 are also in 
position to participate in the catalytic mechanism and point mutations at these sites 
decrease the rate of catalysis relative to the wild type enzyme.  Interestingly, all of these 
residues are conserved in the ssNAT enzyme, where ssNAT residues E84, R178 and 
Y203 correspond to Naa10p residues E24, R113 and Y139.  We found that the sssNAT-
E84Q mutant is only 1.8-fold less active towards the Ser- substrate relative to the wild 
type enzyme.  This result suggests that ssNAT-E84 (at least on its own) does not play an 
analogous general base role as Naa10p-E24 for the Ser- amino terminal substrate.  We 
then addressed the possibility that ssNAT-E84 might cooperate with ssNAT-E176 or 
ssNAT-H137 for Ser- substrate acetylation. Analysis of the ssNAT-E84Q/E176Q and 
ssNAT-E84Q/H137A double mutants revealed that the ssNAT-E84Q/E176Q mutant had 
no detectable activity towards the Ser- amino terminal substrate while the ssNAT-
E84Q/H137A mutant had only a minor effect on catalysis (1.5-fold decrease in kcat) but 
showed a 7.4-fold increase in Km.  We also assessed the effect combining the ssNAT-
E176Q mutant with mutants of either ssNAT-R178 or ssNAT-Y203 and found that the 
ssNAT-E176Q/R178A and ssNAT-E176Q/Y203F mutants had a 2-fold or less decrease 
in kcat towards the Ser- amino-terminal substrate. Taking these results together reveals 
that residues ssNAT-E84 and ssNAT-E176 cooperate as general base residues for ssNAT 
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acetylation through an alternative catalytic strategy (strategy 2) for acetylation of the Ser- 
substrate (Figure 4.2D).  The observation that the ssNAT-E84Q/E176Q mutant is also 
unable to acetylate the Met substrate likely reflects the importance of ssNAT-E176 for 
Met-substrate acetylation in the context of an amino-terminal binding pocket with an 
altered electrostatic environment, which potentially effects the position of the α-amino 
group within the active site. 
 
4.2.4  Non-conserved loop region potentiates ssNAT activity 
Despite a nearly identical active site landscape between ssNAT and Naa10p, 
Naa10p is not able to facilitate catalysis via catalytic strategy 1.  The active site 
alignment shows that ssNAT-Y174 is one of the only residues in the active site that is not 
conserved in Naa10p (Figure 4.2A).  Additionally, this residue appears to play a role in 
positioning ssNAT-H137 for Met- amino-terminal substrate catalysis by forcing this 
general base residue into the active site.  The residue corresponding to ssNAT-Y174 in 
Naa10p, Naa10p-S109, lacks the bulky side chain required to force the corresponding 
base residue, Naa10p-H72, into the active site of the enzyme.  Consequently, the Naa10p-
H72 side chain is able to flip out of the active site into a catalytically incompetent 
position.  Contrary to this hypothesis, the ssNAT-Y174S point mutant, which mimics the 
Naa10p active site, has no effect on catalysis and implies that ssNAT-H137 is held in 
position by other residues in the local environment.  Indeed, inspection of the alignment 
of ssNAT with the Naa10p and Naa50p structures (Figure 4.1B) reveals that the loop 
segment connecting the β3 and β4 strands of the ssNAT core region is significantly more 
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extended than the corresponding loops of Naa10p and Naa50p and points towards the 
ssNAT active site (Figure 4.4A). In particular, residues ssNAT-N125 and ssNAT-I126, at 
the tip of the β3-β4 loop, appear to make intramolecular interactions with the B5 and B7 
strands.  To determine if the β3-β4 loop region participates in catalysis in some way, we 
prepared the ssNAT-N125A/I126A mutant, which we found is unable to acetylate the 
Met- amino-terminal substrate and exhibits a 4.0-fold reduction in kcat towards the Ser- 
amino terminal substrate as well as a 3.9-fold increase in Km relative to the wild type 
enzyme.  Based on this observation, we conclude that the extended β3-β4 loop region of 
ssNAT likely has a stabilizing effect on the three dimensional fold of the active site and is 
able to prime the enzyme for catalysis of the Met- substrate, and to a lesser extent the 
Ser- amino terminal substrate. 
Interestingly, there are several GNAT enzymes that capitalize on the variability of 
the β3-β4 loop region for functional gain (Figure 4.4B).  In glucosamine-6-phosphate 
acetyltransferase (GNA1; PDB ID:  1I1D) and the histone acetyltransferase HPA2 (PDB 
ID:  1QSM), this loop mediates biologically relevant dimerization and facilitates 
substrate binding by contributing to active site architecture of the dimer partner (Figure 
4.4 C and D), while in serotonin N-acetyltransferase (AANAT; PDB ID:  1L0C) this 
region is responsible for orienting the arylalkylamine substrate in the active site through 
an intramolecular mechanism (Figure 4.4E) (Angus-Hill et al., 1999; Peneff et al., 2001; 
Scheibner et al., 2002).    
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Figure 4.4  The β3-β4 loop region in ssNAT and other GNAT enzymes.  (caption on 
following page) 
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Figure 4.4 (continued) (A)  A zoom view of the β3-loop-β4 region of ssNAT.  Key 
residues (shown in tan stick format) and secondary structure elements are labeled.  
AcCoA is represented in gray stick format.  (B)  An alignment of GNA1 (light blue 
cartoon representation), HPA2 (a neon green cartoon representation), AANAT (pink 
cartoon representation
representation, respectively) showing conserved secondary structure elements at 50% 
transparency.  The β3-loop-β4 motifs from these enzymes are shown with no 
transparency.  The variable region has been encircled and labeled.  Key secondary 
structure elements are also labeled. (C) GNA1 (light blue cartoon, 50% transparancy) 
bound to CoA (gray stick representation) and the GlcNAc6P substrate (silver stick 
representation) with key secondary structure elements labeled and the β3-loop-β4 motif 
shown with no transparency.  Secondary structure elements from the β3-loop-β4 motif of 
the second molecule in the dimer (dark blue cartoon representation) are also labeled with 
a (') symbol. (D) HPA2 (neon green cartoon, 50% transparency) bound to AcCoA (gray 
stick representation) with key secondary structure elements labeled and the β3-loop-β4 
motif shown with no transparency.  Secondary structure elements from the β3-loop-β4 
motif of the second molecule in the dimer (dark green cartoon representation) are also 
labeled with a (') symbol. (E) AANAT (light red cartoon, 50% transparency) bound to a 
bisubstrate analogue CoA-S-Acetyltryptamine (silver stick representation) with key 
secondary structure elements labeled and the β3-loop-β4 motif shown with no 
transparency.  The β3-β4 loop is colored in dark red. 
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4.2.5  The length of the α1 helix has implications for obligate heterodimerization of 
certain NAT enzymes 
The C-terminal portion of the α1 helix is the only region of ssNAT that is 
sequentially more similar to Naa50p than to Naa10p (Figure 4.5A).  Interestingly, as 
shown in Figures 4.1B and 4.1C, the length of this helix is critical for the placement of 
the α1-α2 loop, which harbors several residues that facilitate substrate binding and/or 
catalysis in all three NATs discussed here. The independently active ssNAT and Naa50p 
enzymes have similar α-helix-stabilizing residues in the C-terminal portion of the α1 
helix (Figure 4.5A and B), which is able to undergo an additional helical twist relative to 
monomeric Naa10p (Figure 4.1C). As a result, the α1-α2 loop in both ssNAT and Naa50p 
is able to adopt a conformation that is suitable for catalysis in the absence of an auxiliary 
subunit.  In Naa10p, these helix-stabilizing residues are not conserved; consequently, the 
length of the α1 helix and position of the α1-α2 loop cannot support catalysis by the 
enzyme in the absence of auxiliary subunit binding.  It is therefore tempting to speculate 
that the length of this helix may dictate whether or not a NAT enzyme needs a binding 
partner for catalytic activation. 
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Figure 4.5  Conservation between the ssNAT α1-loop-α2 motif and the 
corresponding regions of Naa10p and Naa50p.  (caption on following page) 
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Figure 4.5 (continued) (A) A surface conservation map for ssNAT with Naa10p and 
Naa50p centered on the α1 helix.  Regions in which aligned residues are identical are 
shown in dark red, regions in which aligned residues are highly similar are shown in light 
red, and regions in which aligned residues are not similar are shown in light blue.  Key 
secondary structure elements are labeled. (C) A sequence alignment of the α1-loop-α2 
motif in ssNAT with the corresponding regions of Naa10p and Naa50p.  Secondary 
structure elements observed in the 3-dimensional structure are shown just above the 
sequence.  Residue numbers correspond to ssNAT.  Catalytic and substrate binding 
residues from ssNAT are denoted with a (•) and (✚), respectively, above the residue in 
the sequence. 
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4.3  Discussion 
Because Sulfolobus solfataricus only contains one NAT protein to acetylate 
substrates with different N-terminal residues, it appears this enzyme has a 
“compromised” strategy to acetylate many varied substrates. In particular, we found the 
ssNAT contains an active site that is a hybrid of the NatA and NatE active sites, and as a 
result can facilitate acetylation of Met- and non-Met-containing amino-terminal substrate 
peptides.  We show that while ssNAT has higher sequence similarity to Naa10p over 
Naa50p (34% vs. 24% sequence identity, respectively) and correspondingly has a 
preference for Ser- over Met-amino-terminal substrates, it still is able to accommodate a 
Met- amino-terminal substrate.  Our results indicate that for the Met- amino-terminal 
substrate, ssNAT uses H137 in particular, but also E176 as general base residues for 
catalysis, while it uses E84 and E176 as general base residues for the Ser-amino-terminal 
substrate.  We also show that ssNAT utilizes a structural feature that is not conserved in 
the eukaryotic NATs, the β3-β4 loop, to stabilize the position of key residues involved in 
substrate acetylation, and Met- amino-terminal substrate acetylation in particular. 
The presence of two different catalytic strategies that facilitate the reaction of a 
single enzyme towards different substrates is very rare and, to our knowledge, this is the 
first acetyltransferase to be identified that can carry out the deprotonation event through 
different pathways. One explanation for the existence of the two catalytic strategies is 
that ssNAT represents a ‘snapshot’ in the evolution of the eukaryotic NATs, which 
subsequently evolved into separate enzymes with increased specificity towards different 
substrates. Consequently, we propose that evolutionary events, such as mutations to the 
active site, and the β3-β4 loop region and the C-terminal portion of the α1 helix, led to a 
   132 
diverse family of monomeric and heterodimeric eukaryotic NATs with different substrate 
specificities and catalytic mechanisms.   
 
4.4  Materials and methods 
4.4.1  ssNAT expression and purification 
The ssNAT gene (encoding residues 50-216) was cloned out of Sulfolobus 
solfataricus genomic DNA (ATCC) and engineered into a modified pETDUET vector 
containing a TEV protease cleavable 6X-His tag.  The resulting plasmid was transformed 
into Rosetta (DE3)pLysS competent E. coli cells, grown to an OD600=0.7 and induced 
with 0.5 mM IPTG at 16°C for ~16 hours.  Cells were isolated by centrifugation and 
lysed by sonication in a buffer containing 25 mM Tris (pH 8.0), 1 M NaCl, 10 mM β-ME 
and 0.5mM PMSF (Sigma-Aldrich).  The solution was isolated and passed over Ni-resin 
(Thermo Scientific), which was subsequently washed with > 20 column volumes of lysis 
buffer supplemented with 25 mM imidazole (Fisher Scientific).  The protein was eluted 
in the same buffer with an imidazole gradient (25-500 mM imidazole) and TEV protease 
was added to fractions containing the target protein for the duration of a 14-hour dialysis 
into lysis buffer adjusted to 300 mM NaCl.  The solution was passed through an 
additional nickel column to remove TEV protease as well as any uncut ssNAT.  The resin 
was then washed with ~ 7 column volumes of dialysis buffer supplemented with 25 mM 
imidazole, which was pooled with the initial flow through.  This solution was dialyzed 
into a buffer containing 25mM Tris (pH 8.5), 50 mM NaCl and 5 mM β-ME and loaded 
onto a 5 mL HiTrap Q ion exchange column (GE Healthcare).  Although the protein did 
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not stick to this column, a major impurity did interact with the column and so this step 
was still essential for obtaining high purity protein. Peak fractions were concentrated to 
~1-2 mL (10kDa concentrator; Amicon Ultra, Millipore) and loaded onto an s75prep gel 
filtration column (GE Healthcare) that was pre-equilibrated in a buffer containing 20 mM 
Tris (pH 7.5), 150 mM NaCl and 10% glycerol.  The second of two peaks from the sizing 
column corresponded to monomeric ssNAT and so this peak was pooled and 
concentrated to 10 mg/mL as measured by UV280 absorbance (extinction coefficient = 
25,000), for crystallization trials.  All ssNAT mutants were generated using the 
Stratagene QuickChange protocol and protein harboring point mutations was expressed 
and purified using the protocol described above (Braman et al., 1996).  All mutants 
exhibit gel filtration profiles similar to that of the wild type enzyme, suggesting that they 
are properly folded. 
 
4.4.2  ssNAT crystallization and structure determination.   
Prior to crystallization, ssNAT was mixed with AcCoA (Sigma-Aldrich) at a 1:3 
molar ratio.  Initial crystallization hits were obtained at 20°C using hanging drop vapor 
diffusion with two different well conditions; the first containing 20% PEG 3350 
(Hampton Research) and 0.2 M zinc acetate (Hampton Research) and the second 
containing 20% PEG 3350 and 0.02 M zinc chloride (Hampton Research).  The zinc 
acetate condition showed better initial diffraction and optimization of this condition 
resulted in a well containing 14% PEG 3350 and 0.1 M zinc acetate.  The best diffracting 
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crystals were from a drop set up using a protein concentration of 7.5 mg/mL and took 3-7 
days to reach maximum dimensions. 
Diffraction data were collected on a Rigaku MicroMax-007 HF rotating anode x-
ray generator with a Saturn 944+ CCD detector and processed to 1.98 Å resolution using 
HKL2000 (Otwinowski and Minor, 1997).  A total of 150 degrees (1°/frame) were 
collected and indexed in the C2 space group.  Molecular replacement was performed 
using the program Phaser and the apo structure of ssARD1 (PDB ID:  2X7B) as a search 
model (McCoy et al., 2007).  This solution yielded high electron density maps and initial 
rounds of manual model building and refinement were performed using Coot (Emsley 
and Cowtan, 2004).  Subsequent rounds of refinement were performed using 
Phenix.Refine to refine XYZ coordinates and individual atomic displacement parameters 
(Adams et al., 2010).  Iterative rounds of phenix refine and manual refinement in coot 
were used to reach final Rwork and Rfree values of 19.9% and 24.3%, respectively.  The 
final map was checked for errors using a composite omit map generated by AutoBuild in 
the Phenix suite of programs (Adams et al., 2010). 
All three-dimensional alignment RMSDs as well as graphics were generated in 
PyMol (Delano Scientific LLC). 
 
4.4.3  Acetyltransferase assays 
All assays were performed in the presence of 500 nM ssNAT enzyme at 37°C in a 
buffer containing 25 mM Tris (pH 8.0) and 50 mM NaCl.  It is likely that the in vivo kcat 
values for this enzyme are much higher than we report here because the enzyme is from a 
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thermophilic archaeal species that thrives in environments that reach temperatures much 
greater than 37°C. For Ser- peptide assays, reaction times were generally 30 minutes, 
however, catalytically deficient mutants were tested for up to 2 hours.  For Met- peptides 
assays, reaction times were generally 120 minutes, however, times ranged from 30 
minutes to 6 hours depending on the effect of the mutant.  Mutants that did not show 
activity levels at least 2-fold greater than background readings were considered inactive.  
A saturating amount (500 μM) of radiolabeled [
14
C]acetyl-CoA (4 mCi/mmol; 
PerkinElmer Life Sciences) was used in all enzymatic reactions and the substrate peptide 
concentration was varied to determine steady-state catalytic parameters.  The 
concentration of the Ser- peptide (NH2-SASEAGVRWGRPVGRRRRP-COOH; 
GenScript) ranged from 25-1000 μM.  The first seven residues of this peptide correspond 
to the amino-terminal sequence of a threonyl-tRNA synthetase protein that has been 
shown to be 100% amino-terminally acetylated in yeast and the C-terminal 12 residues 
form a basic tag that is required for compatibility with our filter paper binding assay.  The 
concentration of the Met- peptide (NH2-MLGPEGGRWGRPVGRRRRP-COOH; 
GenScript) ranged from 50-1200 μM.  The first seven residues of this peptide correspond 
to the amino-terminal sequence of hnRNP F, which is the only known biologically 
relevant substrate for the Naa50p enzyme and the C-terminal 12 residues are identical to 
that of the Ser- peptide.  In the assay, radiolabeled [
14
C]AcCoA was mixed with the 
substrate peptide and allowed to incubate with enzyme in a 25 μL reaction volume. To 
quench the reaction, 20 μL of the reaction mixture was added to P81 paper discs 
(Whatman), and the paper discs were immediately placed in wash buffer (10 mM HEPES 
(pH 7.5).  Papers were left submerged in wash buffer under gentle agitation for a total of 
   136 
15 minutes to remove any unreacted AcCoA.  During this process, buffer was discarded 
and replaced with fresh wash buffer every 5 minutes. The papers were then dried with 
acetone and added to 4 ml of scintillation fluid, and the signal was measured using a 
Packard Tri-Carb 1500 liquid scintillation analyzer. Background control reactions were 
performed in the absence of enzyme.  Reactions were also performed in the absence of 
the substrate peptide to ensure that any possible signal due to autoacetylation was 
negligible.  The background signal was accounted for when calculating catalytic 
parameters for the wild type enzyme and mutants.  All radioactive count values were 
converted to molar units using a standard curve created with known concentrations of 
radioactive AcCoA added to scintillation fluid.  The program GraphPad Prism version 
5.01 was used for all data fitting to the Michaelis-Menten equation. 
   137 
REFERENCES 
Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, 
J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. (2010). PHENIX: a 
comprehensive Python-based system for macromolecular structure solution. Acta 
Crystallogr. D Biol. Crystallogr. 66, 213-221. 
Aivaliotis, M., Gevaert, K., Falb, M., Tebbe, A., Konstantinidis, K., Bisle, B., Klein, C., 
Martens, L., Staes, A., Timmerman, E., et al. (2007). Large-scale identification of N-
terminal peptides in the halophilic archaea Halobacterium salinarum and Natronomonas 
pharaonis. J. Proteome Res. 6, 2195-2204. 
Allfrey, V.G., Faulkner, R., and Mirsky, A.E. (1964). Acetylation and Methylation of 
Histones and Their Possible Role in the Regulation of Rna Synthesis. Proc. Natl. Acad. 
Sci. U. S. A. 51, 786-794. 
Angus-Hill, M.L., Dutnall, R.N., Tafrov, S.T., Sternglanz, R., and Ramakrishnan, V. 
(1999). Crystal structure of the histone acetyltransferase Hpa2: A tetrameric member of 
the Gcn5-related N-acetyltransferase superfamily. J. Mol. Biol. 294, 1311-1325. 
Arnesen, T. (2011). Towards a functional understanding of protein N-terminal 
acetylation. PLoS Biol. 9, e1001074. 
Arnesen, T., Anderson, D., Baldersheim, C., Lanotte, M., Varhaug, J.E., and Lillehaug, 
J.R. (2005). Identification and characterization of the human ARD1-NATH protein 
acetyltransferase complex. Biochem. J. 386, 433-443. 
Arnesen, T., Anderson, D., Torsvik, J., Halseth, H.B., Varhaug, J.E., and Lillehaug, J.R. 
(2006a). Cloning and characterization of hNAT5/hSAN: an evolutionarily conserved 
component of the NatA protein N-alpha-acetyltransferase complex. Gene 371, 291-295. 
Arnesen, T., Gromyko, D., Pendino, F., Ryningen, A., Varhaug, J.E., and Lillehaug, J.R. 
(2006b). Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 
and NATH, components of the protein N-alpha-acetyltransferase complex. Oncogene 25, 
4350-4360. 
Arnesen, T., Starheim, K.K., Van Damme, P., Evjenth, R., Dinh, H., Betts, M.J., 
Ryningen, A., Vandekerckhove, J., Gevaert, K., and Anderson, D. (2010). The 
   138 
chaperone-like protein HYPK acts together with NatA in cotranslational N-terminal 
acetylation and prevention of Huntingtin aggregation. Mol. Cell. Biol. 30, 1898-1909. 
Arnesen, T., Thompson, P.R., Varhaug, J.E., and Lillehaug, J.R. (2008). The protein 
acetyltransferase ARD1: a novel cancer drug target? Curr. Cancer Drug Targets 8, 545-
553. 
Arnesen, T., Van Damme, P., Polevoda, B., Helsens, K., Evjenth, R., Colaert, N., 
Varhaug, J.E., Vandekerckhove, J., Lillehaug, J.R., Sherman, F., et al. (2009). 
Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal 
acetyltransferases from yeast and humans. Proc. Natl. Acad. Sci. U. S. A. 106, 8157-
8162. 
Bachmair, A., Finley, D., and Varshavsky, A. (1986). In vivo half-life of a protein is a 
function of its amino-terminal residue. Science 234, 179-186. 
Ben-Shem, A., Garreau de Loubresse, N., Melnikov, S., Jenner, L., Yusupova, G., and 
Yusupov, M. (2011). The structure of the eukaryotic ribosome at 3.0 A resolution. 
Science 334, 1524-1529. 
Ben-Shem, A., Jenner, L., Yusupova, G., and Yusupov, M. (2010). Crystal structure of 
the eukaryotic ribosome. Science 330, 1203-1209. 
Berndsen, C.E., Albaugh, B.N., Tan, S., and Denu, J.M. (2007). Catalytic mechanism of a 
MYST family histone acetyltransferase. Biochemistry 46, 623-629. 
Blatch, G.L., and Lassle, M. (1999). The tetratricopeptide repeat: a structural motif 
mediating protein-protein interactions. Bioessays 21, 932-939. 
Bowers, E.M., Yan, G., Mukherjee, C., Orry, A., Wang, L., Holbert, M.A., Crump, N.T., 
Hazzalin, C.A., Liszczak, G., Yuan, H., et al. (2010). Virtual ligand screening of the 
p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. 
Chem. Biol. 17, 471-482. 
Bradshaw, R.A., Brickey, W.W., and Walker, K.W. (1998). N-terminal processing: the 
methionine aminopeptidase and N alpha-acetyl transferase families. Trends Biochem. 
Sci. 23, 263-267. 
   139 
Braman, J., Papworth, C., and Greener, A. (1996). Site-directed mutagenesis using 
double-stranded plasmid DNA templates. Methods Mol. Biol. 57, 31-44. 
Brent, M.M., Iwata, A., Carten, J., Zhao, K., and Marmorstein, R. (2009). Structure and 
biochemical characterization of protein acetyltransferase from Sulfolobus solfataricus. J. 
Biol. Chem. 284, 19412-19419. 
Brown, J.L., and Roberts, W.K. (1976). Evidence that approximately eighty per cent of 
the soluble proteins from Ehrlich ascites cells are Nalpha-acetylated. J. Biol. Chem. 251, 
1009-1014. 
Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, 
R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., et al. (1998). Crystallography 
& NMR system: A new software suite for macromolecular structure determination. Acta 
Crystallogr. D Biol. Crystallogr. 54, 905-921. 
Carrozza, M.J., Utley, R.T., Workman, J.L., and Cote, J. (2003). The diverse functions of 
histone acetyltransferase complexes. Trends Genet. 19, 321-329. 
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M.L., Rehman, M., Walther, T.C., Olsen, 
J.V., and Mann, M. (2009). Lysine acetylation targets protein complexes and co-regulates 
major cellular functions. Science 325, 834-840. 
Cingolani, G., Petosa, C., Weis, K., and Muller, C.W. (1999). Structure of importin-beta 
bound to the IBB domain of importin-alpha. Nature 399, 221-229. 
Clamp, M., Fry, B., Kamal, M., Xie, X., Cuff, J., Lin, M.F., Kellis, M., Lindblad-Toh, K., 
and Lander, E.S. (2007). Distinguishing protein-coding and noncoding genes in the 
human genome. Proc. Natl. Acad. Sci. U. S. A. 104, 19428-19433. 
Clements, A., Rojas, J.R., Trievel, R.C., Wang, L., Berger, S.L., and Marmorstein, R. 
(1999). Crystal structure of the histone acetyltransferase domain of the human PCAF 
transcriptional regulator bound to coenzyme A. EMBO J. 18, 3521-3532. 
Copeland, R. (2005). Evaluation of Enzyme Inhibitors in Drug Discovery (Wiley-
Interscience). 
   140 
Driessen, H.P., de Jong, W.W., Tesser, G.I., and Bloemendal, H. (1985). The mechanism 
of N-terminal acetylation of proteins. CRC Crit. Rev. Biochem. 18, 281-325. 
Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. 
Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132. 
Evjenth, R., Hole, K., Karlsen, O.A., Ziegler, M., Arnesen, T., and Lillehaug, J.R. (2009). 
Human Naa50p (Nat5/San) displays both protein N alpha- and N epsilon-
acetyltransferase activity. J. Biol. Chem. 284, 31122-31129. 
Falb, M., Aivaliotis, M., Garcia-Rizo, C., Bisle, B., Tebbe, A., Klein, C., Konstantinidis, 
K., Siedler, F., Pfeiffer, F., and Oesterhelt, D. (2006). Archaeal N-terminal protein 
maturation commonly involves N-terminal acetylation: a large-scale proteomics survey. 
J. Mol. Biol. 362, 915-924. 
Fersht, A. (1998). Structure and Mechanism in Protein Science (W.H. Freeman). 
Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J.P., Barsyte-Lovejoy, 
D., Felletar, I., Volkmer, R., Muller, S., Pawson, T., et al. (2012). Histone recognition 
and large-scale structural analysis of the human bromodomain family. Cell 149, 214-231. 
Fluge, O., Bruland, O., Akslen, L.A., Varhaug, J.E., and Lillehaug, J.R. (2002). NATH, a 
novel gene overexpressed in papillary thyroid carcinomas. Oncogene 21, 5056-5068. 
Forte, G.M., Pool, M.R., and Stirling, C.J. (2011). N-terminal acetylation inhibits protein 
targeting to the endoplasmic reticulum. PLoS Biol. 9, e1001073. 
Furdas, S.D., Shekfeh, S., Bissinger, E.M., Wagner, J.M., Schlimme, S., Valkov, V., 
Hendzel, M., Jung, M., and Sippl, W. (2011). Synthesis and biological testing of novel 
pyridoisothiazolones as histone acetyltransferase inhibitors. Bioorg. Med. Chem. 19, 
3678-3689. 
Gautschi, M., Just, S., Mun, A., Ross, S., Rucknagel, P., Dubaquie, Y., Ehrenhofer-
Murray, A., and Rospert, S. (2003). The yeast N(alpha)-acetyltransferase NatA is 
quantitatively anchored to the ribosome and interacts with nascent polypeptides. Mol. 
Cell. Biol. 23, 7403-7414. 
   141 
Giglione, C., Boularot, A., and Meinnel, T. (2004). Protein N-terminal methionine 
excision. Cell. Mol. Life Sci. 61, 1455-1474. 
Gromyko, D., Arnesen, T., Ryningen, A., Varhaug, J.E., and Lillehaug, J.R. (2010). 
Depletion of the human Nalpha-terminal acetyltransferase A induces p53-dependent 
apoptosis and p53-independent growth inhibition. Int. J. Cancer 127, 2777-2789. 
Grunstein, M. (1997). Histone acetylation in chromatin structure and transcription. 
Nature 389, 349-352. 
Helbig, A.O., Gauci, S., Raijmakers, R., van Breukelen, B., Slijper, M., Mohammed, S., 
and Heck, A.J. (2010). Profiling of N-acetylated protein termini provides in-depth 
insights into the N-terminal nature of the proteome. Mol. Cell. Proteomics 9, 928-939. 
Hickman, A.B., Namboodiri, M.A., Klein, D.C., and Dyda, F. (1999). The structural 
basis of ordered substrate binding by serotonin N-acetyltransferase: enzyme complex at 
1.8 A resolution with a bisubstrate analog. Cell 97, 361-369. 
Hodawadekar, S.C., and Marmorstein, R. (2007). Chemistry of acetyl transfer by histone 
modifying enzymes: structure, mechanism and implications for effector design. 
Oncogene 26, 5528-5540. 
Holbert, M.A., Sikorski, T., Carten, J., Snowflack, D., Hodawadekar, S., and 
Marmorstein, R. (2007). The human monocytic leukemia zinc finger histone 
acetyltransferase domain contains DNA-binding activity implicated in chromatin 
targeting. J. Biol. Chem. 282, 36603-36613. 
Hole, K., Van Damme, P., Dalva, M., Aksnes, H., Glomnes, N., Varhaug, J.E., Lillehaug, 
J.R., Gevaert, K., and Arnesen, T. (2011). The human N-alpha-acetyltransferase 40 
(hNaa40p/hNatD) is conserved from yeast and N-terminally acetylates histones H2A and 
H4. PLoS One 6, e24713. 
Hou, F., Chu, C.W., Kong, X., Yokomori, K., and Zou, H. (2007). The acetyltransferase 
activity of San stabilizes the mitotic cohesin at the centromeres in a shugoshin-
independent manner. J. Cell Biol. 177, 587-597. 
Hwang, C.S., Shemorry, A., and Varshavsky, A. (2010). N-terminal acetylation of 
cellular proteins creates specific degradation signals. Science 327, 973-977. 
   142 
Iizuka, M., and Stillman, B. (1999). Histone acetyltransferase HBO1 interacts with the 
ORC1 subunit of the human initiator protein. J. Biol. Chem. 274, 23027-23034. 
Kalvik, T.V., and Arnesen, T. (2013). Protein N-terminal acetyltransferases in cancer. 
Oncogene 32, 269-276. 
Karpenahalli, M.R., Lupas, A.N., and Soding, J. (2007). TPRpred: a tool for prediction of 
TPR-, PPR- and SEL1-like repeats from protein sequences. BMC Bioinformatics 8, 2. 
Kirkland, P.A., Humbard, M.A., Daniels, C.J., and Maupin-Furlow, J.A. (2008). Shotgun 
proteomics of the haloarchaeon Haloferax volcanii. J. Proteome Res. 7, 5033-5039. 
Kouzarides, T. (2000). Acetylation: a regulatory modification to rival phosphorylation? 
EMBO J. 19, 1176-1179. 
Kramer, G., Boehringer, D., Ban, N., and Bukau, B. (2009). The ribosome as a platform 
for co-translational processing, folding and targeting of newly synthesized proteins. Nat. 
Struct. Mol. Biol. 16, 589-597. 
Kuo, M.H., and Allis, C.D. (1998). Roles of histone acetyltransferases and deacetylases 
in gene regulation. Bioessays 20, 615-626. 
Langer, G., Cohen, S.X., Lamzin, V.S., and Perrakis, A. (2008). Automated 
macromolecular model building for X-ray crystallography using ARP/wARP version 7. 
Nature Protocols 3, 1171-1179. 
Langer, M.R., Tanner, K.G., and Denu, J.M. (2001). Mutational analysis of conserved 
residues in the GCN5 family of histone acetyltransferases. J. Biol. Chem. 276, 31321-
31331. 
Lim, J.H., Park, J.W., and Chun, Y.S. (2006). Human arrest defective 1 acetylates and 
activates beta-catenin, promoting lung cancer cell proliferation. Cancer Res. 66, 10677-
10682. 
Line, A., Stengrevics, A., Slucka, Z., Li, G., Jankevics, E., and Rees, R.C. (2002). 
Serological identification and expression analysis of gastric cancer-associated genes. Br. 
J. Cancer 86, 1824-1830. 
   143 
Liszczak, G., Arnesen, T., and Marmorstein, R. (2011). Structure of a ternary Naa50p 
(NAT5/SAN) N-terminal acetyltransferase complex reveals the molecular basis for 
substrate-specific acetylation. J. Biol. Chem. 286, 37002-37010. 
Liu, X., Wang, L., Zhao, K., Thompson, P.R., Hwang, Y., Marmorstein, R., and Cole, 
P.A. (2008). The structural basis of protein acetylation by the p300/CBP transcriptional 
coactivator. Nature 451, 846-850. 
Mackay, D.T., Botting, C.H., Taylor, G.L., and White, M.F. (2007). An acetylase with 
relaxed specificity catalyses protein N-terminal acetylation in Sulfolobus solfataricus. 
Mol. Microbiol. 64, 1540-1548. 
Marmorstein, R. (2004). Biochemical and structural characterization of recombinant 
histone acetyltransferase proteins. Methods Enzymol. 376, 106-119. 
McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and 
Read, R.J. (2007). Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674. 
Midorikawa, Y., Tsutsumi, S., Taniguchi, H., Ishii, M., Kobune, Y., Kodama, T., 
Makuuchi, M., and Aburatani, H. (2002). Identification of genes associated with 
dedifferentiation of hepatocellular carcinoma with expression profiling analysis. Jpn. J. 
Cancer Res. 93, 636-643. 
Mujtaba, S., Zeng, L., and Zhou, M.M. (2007). Structure and acetyl-lysine recognition of 
the bromodomain. Oncogene 26, 5521-5527. 
Mullen, J.R., Kayne, P.S., Moerschell, R.P., Tsunasawa, S., Gribskov, M., Colavito-
Shepanski, M., Grunstein, M., Sherman, F., and Sternglanz, R. (1989). Identification and 
characterization of genes and mutants for an N-terminal acetyltransferase from yeast. 
EMBO J. 8, 2067-2075. 
Narita, K. (1958). Isolation of acetylpeptide from enzymic digests of TMV-protein. 
Biochim. Biophys. Acta 28, 184-191. 
Neuwald, A.F., and Landsman, D. (1997). GCN5-related histone N-acetyltransferases 
belong to a diverse superfamily that includes the yeast SPT10 protein. Trends Biochem. 
Sci. 22, 154-155. 
   144 
Otwinowski, Z., and Minor, W. (1997). Processing of X-ray Diffraction Data Collected in 
Oscillation Mode. Methods Enzymol. 276, 307-326. 
Painter, J., and Merritt, E.A. (2005). A molecular viewer for the analysis of TLS rigid-
body motion in macromolecules. Acta Crystallogr. D Biol. Crystallogr. 61, 465-471. 
Painter, J., and Merritt, E.A. (2006). Optimal description of a protein structure in terms of 
multiple groups undergoing TLS motion. Acta Crystallogr. D Biol. Crystallogr. 62, 439-
450. 
Park, E.C., and Szostak, J.W. (1992). ARD1 and NAT1 proteins form a complex that has 
N-terminal acetyltransferase activity. EMBO J. 11, 2087-2093. 
Parthun, M.R., Widom, J., and Gottschling, D.E. (1996). The major cytoplasmic histone 
acetyltransferase in yeast: links to chromatin replication and histone metabolism. Cell 87, 
85-94. 
Peneff, C., Mengin-Lecreulx, D., and Bourne, Y. (2001). The crystal structures of Apo 
and complexed Saccharomyces cerevisiae GNA1 shed light on the catalytic mechanism 
of an amino-sugar N-acetyltransferase. J. Biol. Chem. 276, 16328-16334. 
Pimenta-Marques, A., Tostoes, R., Marty, T., Barbosa, V., Lehmann, R., and Martinho, 
R.G. (2008). Differential requirements of a mitotic acetyltransferase in somatic and germ 
line cells. Dev. Biol. 323, 197-206. 
Polevoda, B., Brown, S., Cardillo, T.S., Rigby, S., and Sherman, F. (2008). Yeast 
N(alpha)-terminal acetyltransferases are associated with ribosomes. J. Cell. Biochem. 
103, 492-508. 
Polevoda, B., Cardillo, T.S., Doyle, T.C., Bedi, G.S., and Sherman, F. (2003). Nat3p and 
Mdm20p are required for function of yeast NatB Nalpha-terminal acetyltransferase and 
of actin and tropomyosin. J. Biol. Chem. 278, 30686-30697. 
Polevoda, B., Hoskins, J., and Sherman, F. (2009). Properties of Nat4, an N(alpha)-
acetyltransferase of Saccharomyces cerevisiae that modifies N termini of histones H2A 
and H4. Mol. Cell. Biol. 29, 2913-2924. 
   145 
Polevoda, B., Norbeck, J., Takakura, H., Blomberg, A., and Sherman, F. (1999). 
Identification and specificities of N-terminal acetyltransferases from Saccharomyces 
cerevisiae. EMBO J. 18, 6155-6168. 
Polevoda, B., and Sherman, F. (2001). NatC Nalpha-terminal acetyltransferase of yeast 
contains three subunits, Mak3p, Mak10p, and Mak31p. J. Biol. Chem. 276, 20154-20159. 
Polevoda, B., and Sherman, F. (2003a). Composition and function of the eukaryotic N-
terminal acetyltransferase subunits. Biochem. Biophys. Res. Commun. 308, 1-11. 
Polevoda, B., and Sherman, F. (2003b). N-terminal acetyltransferases and sequence 
requirements for N-terminal acetylation of eukaryotic proteins. J. Mol. Biol. 325, 595-
622. 
Poux, A.N., Cebrat, M., Kim, C.M., Cole, P.A., and Marmorstein, R. (2002). Structure of 
the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor. Proc. Natl. Acad. 
Sci. U. S. A. 99, 14065-14070. 
Rapoport, T.A. (1992). Transport of proteins across the endoplasmic reticulum 
membrane. Science 258, 931-936. 
Ren, T., Jiang, B., Jin, G., Li, J., Dong, B., Zhang, J., Meng, L., Wu, J., and Shou, C. 
(2008). Generation of novel monoclonal antibodies and their application for detecting 
ARD1 expression in colorectal cancer. Cancer Lett. 264, 83-92. 
Rigaut, G., Shevchenko, A., Rutz, B., Wilm, M., Mann, M., and Seraphin, B. (1999). A 
generic protein purification method for protein complex characterization and proteome 
exploration. Nat. Biotechnol. 17, 1030-1032. 
Rojas, J.R., Trievel, R.C., Zhou, J., Mo, Y., Li, X., Berger, S.L., Allis, C.D., and 
Marmorstein, R. (1999). Structure of Tetrahymena GCN5 bound to coenzyme A and a 
histone H3 peptide. Nature 401, 93-98. 
Scheibner, K.A., De Angelis, J., Burley, S.K., and Cole, P.A. (2002). Investigation of the 
roles of catalytic residues in serotonin N-acetyltransferase. J. Biol. Chem. 277, 18118-
18126. 
   146 
Scott, D.C., Monda, J.K., Bennett, E.J., Harper, J.W., and Schulman, B.A. (2011). N-
terminal acetylation acts as an avidity enhancer within an interconnected multiprotein 
complex. Science 334, 674-678. 
Seo, J.H., Cha, J.H., Park, J.H., Jeong, C.H., Park, Z.Y., Lee, H.S., Oh, S.H., Kang, J.H., 
Suh, S.W., Kim, K.H., et al. (2010). Arrest defective 1 autoacetylation is a critical step in 
its ability to stimulate cancer cell proliferation. Cancer Res. 70, 4422-4432. 
Song, O.K., Wang, X., Waterborg, J.H., and Sternglanz, R. (2003). An Nalpha-
acetyltransferase responsible for acetylation of the N-terminal residues of histones H4 
and H2A. J. Biol. Chem. 278, 38109-38112. 
Soppa, J. (2010). Protein acetylation in archaea, bacteria, and eukaryotes. Archaea 2010. 
Starheim, K.K., Arnesen, T., Gromyko, D., Ryningen, A., Varhaug, J.E., and Lillehaug, 
J.R. (2008). Identification of the human N(alpha)-acetyltransferase complex B (hNatB): a 
complex important for cell-cycle progression. Biochem. J. 415, 325-331. 
Starheim, K.K., Gevaert, K., and Arnesen, T. (2012). Protein N-terminal 
acetyltransferases: when the start matters. Trends Biochem. Sci. 37, 152-161. 
Starheim, K.K., Gromyko, D., Evjenth, R., Ryningen, A., Varhaug, J.E., Lillehaug, J.R., 
and Arnesen, T. (2009a). Knockdown of human N alpha-terminal acetyltransferase 
complex C leads to p53-dependent apoptosis and aberrant human Arl8b localization. 
Mol. Cell. Biol. 29, 3569-3581. 
Starheim, K.K., Gromyko, D., Velde, R., Varhaug, J.E., and Arnesen, T. (2009b). 
Composition and biological significance of the human Nalpha-terminal 
acetyltransferases. BMC Proceedings 3 Suppl 6, S3. 
Sterner, D.E., and Berger, S.L. (2000). Acetylation of histones and transcription-related 
factors. Microbiol. Mol. Biol. Rev. 64, 435-459. 
Sutton, A., Shia, W.J., Band, D., Kaufman, P.D., Osada, S., Workman, J.L., and 
Sternglanz, R. (2003). Sas4 and Sas5 are required for the histone acetyltransferase 
activity of Sas2 in the SAS complex. J. Biol. Chem. 278, 16887-16892. 
   147 
Tanner, K.G., Trievel, R.C., Kuo, M.H., Howard, R.M., Berger, S.L., Allis, C.D., 
Marmorstein, R., and Denu, J.M. (1999). Catalytic mechanism and function of invariant 
glutamic acid 173 from the histone acetyltransferase GCN5 transcriptional coactivator. J. 
Biol. Chem. 274, 18157-18160. 
Tercero, J.C., Dinman, J.D., and Wickner, R.B. (1993). Yeast MAK3 N-acetyltransferase 
recognizes the N-terminal four amino acids of the major coat protein (gag) of the L-A 
double-stranded RNA virus. J. Bacteriol. 175, 3192-3194. 
Tercero, J.C., and Wickner, R.B. (1992). MAK3 encodes an N-acetyltransferase whose 
modification of the L-A gag NH2 terminus is necessary for virus particle assembly. J. 
Biol. Chem. 267, 20277-20281. 
Terwilliger, T.C. (2000). Maximum-likelihood density modification. Acta Crystallogr. D 
Biol. Crystallogr. 56, 965-972. 
Terwilliger, T.C., and Berendzen, J. (1999). Automated MAD and MIR structure 
solution. Acta Crystallogr. D Biol. Crystallogr. 55, 849-861. 
Trievel, R.C., Rojas, J.R., Sterner, D.E., Venkataramani, R.N., Wang, L., Zhou, J., Allis, 
C.D., Berger, S.L., and Marmorstein, R. (1999). Crystal structure and mechanism of 
histone acetylation of the yeast GCN5 transcriptional coactivator. Proc. Natl. Acad. Sci. 
U. S. A. 96, 8931-8936. 
Van Damme, P., Evjenth, R., Foyn, H., Demeyer, K., De Bock, P.J., Lillehaug, J.R., 
Vandekerckhove, J., Arnesen, T., and Gevaert, K. (2011a). Proteome-derived peptide 
libraries allow detailed analysis of the substrate specificities of N(alpha)-
acetyltransferases and point to hNaa10p as the post-translational actin N(alpha)-
acetyltransferase. Mol. Cell. Proteomics 10, M110 004580. 
Van Damme, P., Hole, K., Pimenta-Marques, A., Helsens, K., Vandekerckhove, J., 
Martinho, R.G., Gevaert, K., and Arnesen, T. (2011b). NatF contributes to an 
evolutionary shift in protein N-terminal acetylation and is important for normal 
chromosome segregation. PLoS Genet. 7, e1002169. 
Van Damme, P., Lasa, M., Polevoda, B., Gazquez, C., Elosegui-Artola, A., Kim, D.S., 
De Juan-Pardo, E., Demeyer, K., Hole, K., Larrea, E., et al. (2012). N-terminal acetylome 
analyses and functional insights of the N-terminal acetyltransferase NatB. Proc. Natl. 
Acad. Sci. U. S. A. 109, 12449-12454. 
   148 
Varshavsky, A. (2011). The N-end rule pathway and regulation by proteolysis. Protein 
Sci. 
Vetting, M.W., Bareich, D.C., Yu, M., and Blanchard, J.S. (2008). Crystal structure of 
RimI from Salmonella typhimurium LT2, the GNAT responsible for N(alpha)-acetylation 
of ribosomal protein S18. Protein Sci. 17, 1781-1790. 
Vetting, M.W., LP, S.d.C., Yu, M., Hegde, S.S., Magnet, S., Roderick, S.L., and 
Blanchard, J.S. (2005). Structure and functions of the GNAT superfamily of 
acetyltransferases. Arch. Biochem. Biophys. 433, 212-226. 
Waller, J.P. (1963). The Nh2-Terminal Residues of the Proteins from Cell-Free Extracts 
of E. Coli. J. Mol. Biol. 7, 483-496. 
Walsh, C.T., Garneau-Tsodikova, S., and Gatto, G.J., Jr. (2005). Protein posttranslational 
modifications: the chemistry of proteome diversifications. Angew. Chem. Int. Ed. Engl. 
44, 7342-7372. 
Wang, L., Tang, Y., Cole, P.A., and Marmorstein, R. (2008). Structure and chemistry of 
the p300/CBP and Rtt109 histone acetyltransferases: implications for histone 
acetyltransferase evolution and function. Curr. Opin. Struct. Biol. 18, 741-747. 
Williams, B.C., Garrett-Engele, C.M., Li, Z., Williams, E.V., Rosenman, E.D., and 
Goldberg, M.L. (2003). Two putative acetyltransferases, san and deco, are required for 
establishing sister chromatid cohesion in Drosophila. Curr. Biol. 13, 2025-2036. 
Wu, J., Wang, J., Li, M., Yang, Y., Wang, B., and Zheng, Y.G. (2011). Small molecule 
inhibitors of histone acetyltransferase Tip60. Bioorg. Chem. 39, 53-58. 
Yan, Y., Harper, S., Speicher, D.W., and Marmorstein, R. (2002). The catalytic 
mechanism of the ESA1 histone acetyltransferase involves a self-acetylated intermediate. 
Nat. Struct. Biol. 9, 862-869. 
Yi, C.H., Pan, H., Seebacher, J., Jang, I.H., Hyberts, S.G., Heffron, G.J., Vander Heiden, 
M.G., Yang, R., Li, F., Locasale, J.W., et al. (2011). Metabolic regulation of protein N-
alpha-acetylation by Bcl-xL promotes cell survival. Cell 146, 607-620. 
   149 
Yu, M., Gong, J., Ma, M., Yang, H., Lai, J., Wu, H., Li, L., Li, L., and Tan, D. (2009a). 
Immunohistochemical analysis of human arrest-defective-1 expressed in cancers in vivo. 
Oncol. Rep. 21, 909-915. 
Yu, M., Ma, M., Huang, C., Yang, H., Lai, J., Yan, S., Li, L., Xiang, M., and Tan, D. 
(2009b). Correlation of expression of human arrest-defective-1 (hARD1) protein with 
breast cancer. Cancer Invest. 27, 978-983. 
Yuan, H., and Marmorstein, R. (2013). Histone Acetyltransferases: Rising ancient 
counterparts to protein kinases. Biopolymers 99, 98-111. 
Yuan, H., Rossetto, D., Mellert, H., Dang, W., Srinivasan, M., Johnson, J., Hodawadekar, 
S., Ding, E.C., Speicher, K., Abshiru, N., et al. (2012). MYST protein acetyltransferase 
activity requires active site lysine autoacetylation. EMBO J. 31, 58-70. 
Yun, M., Wu, J., Workman, J.L., and Li, B. (2011). Readers of histone modifications. 
Cell Res. 21, 564-578. 
 
 
